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ABSTRACT
This thesis evaluates the radiobiological effectiveness of three new boron compounds namely a
boronated porphyrin (BOPP) and two liposome formulations for neutron capture therapy
(BNCT). The methodology utilizes in vitro and in vivo comparisons that characterize compounds
relative to boric acid and boronophenylalanine (BPA).
In vitro evaluations utilized a colorimetric assay and 96-well plates to minimize the quantities of
compound required for testing. The assay was optimized for the murine SCCVII, squamous cell
carcinoma to determine the chemical toxicity and relative cellular uptake of a compound. BOPP
was toxic at low concentrations and comparisons between the different compounds for thermal
neutron irradiations were performed with approximately 5 Pg 10B/ml in the culture medium to
allow radiation induced effects to govern the observed response. Using less than 300 gg of
compound and 250 kVp X-rays as control irradiations, a compound biological effectiveness
(CBE) of 3.3 ± 0.7 was determined for BOPP that is comparable to the result for boric acid (3.5 ±
0.5) indicating a non-selective intracellular accumulation of '0B. BPA has a significantly higher
CBE of 6.1 + 0.7.
Boronated liposomes (MAC-16 and MAC+TAC) were evaluated with the EMT-6 murine
mammary carcinoma. Biodistribution studies showed high '0B uptake in tumor (20-40 jig '0B/g)
30 hours after a single i.v. injection (dose 6-20 pg 1oB per gram of body weight). Tumor control
experiments were performed using thermal neutrons to study the efficacy of the boron delivered
by liposomes and BPA. The MAC-16 produced a 16 % tumor control and BPA (dose 43 jig
l'oB/gbw) 63 % for tumor boron concentrations of approximately 20 jig 'oB/g and the same
neutron fluence. Liposome doses were limited by injection volume and so two injections were
tried 2-hours apart that doubled the boron concentration in tumor compared to a single
administration. This improved the therapeutic response to 67 % with less apparent skin damage
than with BPA. Microscopic studies using fluorescent labeled liposomes revealed '0B was non-
uniformly distributed and concentrated at the edge of the tumor.
Based on these studies in the tumor cell lines chosen neither of the compounds appear superior to
BPA.
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CHAPTER ONE
INTRODUCTION
1-1. Background of BNCT
Boron neutron capture therapy (BNCT) is an experimental type of binary radiation
therapy which aims to treat some cancer types difficult to successfully treat with
conventional therapies such as the malignant brain tumor, glioblastoma multiforme (GBM).
The principle of BNCT was first introduced by G.L. Locher in 1936, only 4 years after the
neutron was discovered [1]. BNCT is based on the capture interaction of a thermal neutron
with boron-10 (I0B), which has a very high thermal neutron capture cross-section (3837
barns, 1 barn = 10-24 cm 2 [2]). BNCT is carried out in two steps: 1) the tumor must be
selectively loaded with a I0B-labeled compound and 2) the tumor region, usually including
some surrounding normal tissues, is irradiated with low energy neutrons. The nontoxic
stable isotope of natural boron, IoB, and the low energy neutrons each have only minor
effects on normal tissue. However, when these two components are combined, very
localized and lethal radiation damage is produced in the tumor cells containing loB. This
selective energy deposition from 'oB is based upon the following neutron capture reaction:
IoB + In -* ["B] - 7Li + 4He + 2.31 MeV + y (0.48 MeV) (94 %)
10B + I'n * ["iB]- 7Li+ 4He + 2.79 MeV (6 %)
that is more likely with neutrons in the thermal energy range (Eth < 0.4 eV) [2]. The
secondary charged particles have very short ranges in tissue of approximately 9 pm for the
a particle and 5 pm for the 7Li ion [2]; these distances are comparable to the diameter of a
mammalian cell [3]. Thus, these particles result in highly selective damage constrained
mostly to tumor cells containing '0B. Figure 1.1 illustrates the l0B(n,a) 7Li nuclear reaction
in the cell. If a boron compound with satisfactory tumor selectivity and uptake is used with
a neutron beam achieving a uniform and adequate neutron fluence in the treatment volume,
then BNCT can potentially destroy not only the bulk tumor but also the associated
infiltrating tumor cells in the surrounding normal tissue [4]. Therefore, BNCT is a cellular
targeting radiation therapy.
Figure 1.1. Schematic of the 'oB(n,a) 7Li reaction in a cell. 10B captures a thermal neutron
and splits into two highly energetic particles, alpha and recoiling 7Li ions, with energies of
1.47 and 0.84 MeV, respectively.
The first clinical studies of BNCT for GBM were initiated in the 1950s and early
1960s at Brookhaven National Laboratory (BNL) and Massachusetts General Hospital
(MGH)/Massachusetts Institute of Technology (MIT) [5]. These efforts to prolong patient
life were discouraging due to two major factors: 1) poor penetration of the thermal neutron
beam at the depth of the tumor site and 2) inadequate selective accumulation of 10B in
tumor relative to blood and skin [4]. As boron delivery agents, inorganic salts such as
borax, p-carboxyphenylboronic acid, sodium perhydrodecaborate, or sodium pentaborate
were used, but these compounds had no tumor-seeking properties [6]. They could
accumulate in some parts of tumor because of damaged or absent blood-brain barrier but
were not able to cross the intact blood-brain barrier in the normal brain. Tumors recurred





radiation damage to skin and brain [7]. The clinical trials in the United States were
therefore discontinued after 1962. BNCT clinical studies for GBM were restarted in Japan
in the late 1960s utilizing sulfhydryl borane (BSH, Na2B12H11SH) developed as a boron
compound by Soloway at MGH [8]. These trials indicated that BSH accumulated
selectively in tumors. Still, poor penetration of the available thermal neutron beams
remained a problem. The Japanese approaches used thermal neutrons in an open surgical
cavity either at the time of initial craniotomy or a re-opened craniotomy [9]. In the USA,
BNCT studies were restarted in the 1990s following the improvement of neutron beams and
the development of new boron compounds, especially borono-phenylalanine-fructose
(BPA-F) [10]. Beams of higher-energy epithermal neutrons (0.5 eV < Eepi < 10 keV) were
designed and constructed with the ability to deliver a significant thermal neutron fluence to
deep seated (> 8cm) brain tumors minimizing damage to skin and intervening normal
tissues [11, 12]. Several trials using BPA-F were completed for GBM at BNL [13-15], and
for GBM and melanoma at Harvard-MIT [16]. These studies produced median survival
times (-12-13 months) comparable to standard conventional therapy for GBM patients [2].
In Sweden, trials with long-term, 6 hour, infusions of BPA-F reported better median
survival (18 months) of GBM patients [2]. However, histopathological examination of
GBM patients after BPA-F mediated BNCT at the BNL showed tumor recurrence in high
radiation dose regions as well as radiation-induced tumor necrosis [15]. Although there
were some successful outcomes using these compounds, one of the main conclusions from
these clinical trials was that 10B was not uniformly delivered to all tumor cells. Recent
clinical trials at MIT were discontinued in 2003. Currently, BNCT clinical trials for brain
tumors as well as melanoma continue in Argentina [17, 18], Europe including Finland [19],
the Netherlands [20] and are to commence in the UK, Italy, and China. In Japan, clinical
trials of brain cancer continue [21-23] and head and neck tumors are now being
investigated [24, 25].
1-2. Dose components and biological effectiveness of BNCT radiation
The total BNCT radiation dose in tissue is comprised of several different
components: the neutron-capture products of the l'oB(n,ct) 7Li reaction and the nonspecific
background dose from the interaction of the neutron beam with elements in tissue. In both
tumor and normal tissue, radiation dose results from the 590 keV protons released from the
14N(n,p) 14C (cross-section: 1.88 barns) reaction with nitrogen in tissue and the gamma rays
released by the abundant amount of hydrogen in tissue from the 'H(n,y) 2H (cross-section:
0.33 barns) reactions. Additional dose may be contributed by the recoil protons from the
contaminating fast neutrons that elastically scatter with hydrogen ('H(n,n')'H) and by
gamma rays in the neutron beam [4]. These last two contributions are beam-specific and are
very minor in most recent beam lines designed specifically for BNCT such as the thermal
neutron beam at the MIT Research Reactor (MITR-II).
The BNCT dose components in tissue have different biological effectiveness because
they have different linear energy transfer (LET) characteristics. In order to compare the
total effects of BNCT or neutron irradiations with conventional photon irradiation, relative
biological effectiveness (RBE) factors need to be determined experimentally. The term of
compound biological effectiveness (CBE) factor is introduced in BNCT, because the
biological effectiveness of the l0B dose is also influenced by the microdistribution of boron
in tissue which is characteristic of each boron compound.
1-3. Boron delivery agents
BNCT requires that physical and biological optimizations be performed. During the
1990s, physical optimization was completed with development of nearly optimum
epithermal neutron beams [ 11]. As realized in the clinical trials, the success of BNCT
depends upon the ability of a boron compound to preferentially and homogeneously deliver
'
0B to malignant tissue. However, no new boron compound has been approved for clinical
BNCT in over 20 years. Several groups in the USA have developed new boron compounds
and the BNCT User Center at the MIT provides the pre-clinical evaluation of boron
compounds [26]. This thesis includes the development and optimization for evaluation
methods of boron compounds.
There are critical requirements for a promising boron delivery agent: 1) low systemic
toxicity, 2) rapid clearance from blood and normal tissue and retention in tumor during
irradiation, 3) highly specific uptake in tumor with high ratios of tumor-to-blood and
tumor-to-normal-tissue loB concentrations, and 4) at least 20-30 ýtg loB per gram of tumor
to produce a significant l0B capture-dose to the tumor that is approximately twice the
nonspecific beam background doses that affect both tumor and normal tissue [27]. During
BNCT, a maximum fluence of _1012 thermal neutrons/cm 2 can be tolerated by normal brain
tissue, and 109 atoms of l'oB per tumor cell are needed to create approximately 3-4 boron
neutron capture events in that cell. With the assumption of 109 cells per one gram of tissue,
109 10B atoms per cell represent a bulk concentration of -30 tg l'oB/g tumor [2].
Currently, only two boron compounds have been used in clinical BNCT trials: 1) the
amino acid analogue p-boronophenylalanine (BPA, C9HI2NO4B) and 2) the sulfhydryl
borane (BSH, Na2B12H1 SH). The chemical structures of BPA and BSH are presented in
Figure 1.2. Although BPA was first synthesized in the late 1950s for BNCT, the fact that
BPA penetrates the blood-brain barrier was considered as a disadvantage at the time for the
treatment of brain tumors due to high doses to normal brain. Since being initially evaluated
as a boron delivery agent for melanoma because of its similar structure to tyrosine, the
precursor of melanin, in 1970s' Japanese studies, BPA has been actively investigated [4].
With a tumor-to-blood l'oB concentration ratio of -4: 1, this selective uptake of BPA in brain
tumor may rely on the active amino acid transport mechanism [28]. BPA has been used in
the treatment of malignant melanomas and was also utilized in the treatment of brain
tumors [29]. At BNL, studies in a rat brain tumor model showed that long-term infusions
(6-24 hours) of BPA-F produced better accumulation of boron in tumor cells infiltrating the
normal brain compared to the 2-hour infusions [30].
BSH has been utilized for the treatment of brain tumors [31]. A small cage-structure
compound, BSH is unable to cross the intact blood-brain barrier. BSH can be passively
accumulated in parts of the tumor without an intact blood-brain barrier and achieve tumor-
to-blood l'oB concentration ratios ranging from 0.9:1 to 2:1 [4]. Even though BSH has a low
tumor-to-blood l'oB concentration ratio, BSH has been used for the treatment of brain
tumors because of its exclusion from normal brain due to the blood-brain barrier [32].
However, some Japanese clinical trials reported acute and late radiation damage in normal
brain because of the boron existing in the blood vessels of the normal brain during BNCT.
Thus, in order to prevent the late radiation damage, a limit on the calculated l0B dose of 12
Gy was suggested for the endothelial cells of the vasculature in the normal brain. This
vascular dose was calculated by applying a geometry factor that boron dose absorbed in the
capillary wall was a third of the boron dose absorbed in the blood [33].
Figure 1.2. The chemical structures of p-boronophenylalanine (BPA) and the sulfhydryl
borane (BSH), the two compounds used worldwide in current clinical BNCT trials [2].
Although the boron compounds BPA and BSH may be expected to provide more IoB
capture-dose to bulk tumors than to normal tissue, the ratio of the tumor-to-normal-tissue
dose is far from what should be achieved for effective BNCT. Moreover, there are
indications that BPA and BSH do not reach every tumor cell with an adequate 1oB
concentration and that not all malignant cells are eradicated during BNCT. Thus, other
classes of boron delivery agents have been designed and synthesized in attempting to attain
the requirements for successful BNCT mentioned above. These types of compounds
include other boron-containing amino acids, biochemical precursors of nucleic acids, DNA-
targeting molecules, receptor-binding molecules, monoclonal antibodies, liposomes, and
porphyrin derivatives [27]. Several review articles have comprehensively described the
wide variety of boron compounds that have been synthesized [34-36].
Many compounds have been developed; however, only a few have been tested in
vitro, with fewer tested in vivo, and none have yet begun a Phase I clinical study [37].
Boronated monoclonal antibodies against epidermal growth factor receptor for example
have produced promising results using a glioma-bearing rat model [38, 39]. Extensive
studies have demonstrated that a variety of boronated porphyrins can target various tumor










These porphyrins have attractive properties of high boron affinity to tumor, an exceedingly
high tumor-to-blood concentration ratio, and long retention time in tumors [44]. Porphyrin-
mediated BNCT in the murine EMT-6 mammary carcinoma produced effective tumor
response using multiple injections of the carboranylporphyrin (CuTCPH) [45]. Moreover, a
radiation response study of oral mucosa showed that boron was not delivered to the
sensitive epithelial stem cells of oral mucosa, suggesting that porphyrins may be of use for
BNCT of head and neck tumors [46].
In conclusion, the development of better boron compounds is critical to the
successful routine exploitation of neutron capture therapy as a useful modality. Moreover,
the possibility of applying BNCT to a wide variety of tumor sites and tumor types makes an
efficient and accurate methodology for evaluating boron compounds a very important part
of boron compound development.
1-4. Research objectives and thesis organization
The overall objective of this research is to improve the effectiveness of BNCT
through the identification of better boron compounds. An efficient and accurate
methodology is desired to evaluate the radiobiological effectiveness of newly synthesized
boron compounds. Boron compounds have to be tested with different evaluation methods
depending upon their stages of compound development. An in vitro compound screening
system is suitable in order to demonstrate promising agents with low chemical toxicity and
selective intracellular uptake of compound in the early stage of compound development
prior to further in vivo study. In vivo evaluation of a new boron compound is the
culminating procedure for establishing the effectiveness of a compound in a small animal
tumor model for BNCT since favorable animal trial results are required before clinical
study in humans.
In vitro compound screening: Chapter 2 describes the development of an in vitro
compound screening method using the SCCVII mouse squamous cell carcinoma cell line; a
murine model of head and neck cancer. This cell line was chosen as a representative class
of tumor that could be treated in the future with BNCT. Clonogenic and colorimetric assays
were utilized to assess the cell response with newly developed compounds, which are
appropriate for low molecular weight compounds that can readily permeate soft tissue.
Because cell irradiations had not previously been performed for characterizing boron
compounds at the MITR-II, the cell irradiation facility had to be built and optimized.
Chemical synthesis is often time-consuming and expensive, so minimizing the amount of
compound needed is an important factor that was considered in the design and optimization
of cell irradiation facilities. In order to determine the relative intracellular accumulation of a
compound, boric acid and BPA were used as reference compounds since the characteristics
of cellular uptake for these compounds are well known. The comparison of the cell survival
curves with boric acid, BPA, and test compounds gives an indirect estimation of relative
intracellular accumulation of test compounds. The specific goals also include measuring
dose, irradiating cells, and determining curves fitted to the linear-quadratic model of cell
survival. To quantitatively analyze the biological efficacy of any new boron compound,
CBE factors are calculated. Methodology is described for a rigorous uncertainty analysis of
the neutron beam RBE and the boron compound CBE factor.
In vivo evaluation of boronated liposomes: Chapter 3 provides original results from
animal studies using boronated liposomes, a new class of boron delivery agent, evaluated
for BNCT in the EMT-6 murine mammary carcinoma model for consistency of previous
uptake studies. Liposomes are small unilamellar vesicles which consist of a phospholipids
bilayer and an interior aqueous core with diameters of 60-100 nm. In vivo evaluations for
two formulations of boronated liposomes (MAC and MAC+TAC) were completed
including biodistribution, microdistribution, and therapeutic response studies. As a
benchmark, the liposome results were compared with those from BPA, one of the boron
compounds approved for clinical trials of BNCT. In Chapter 4, two approaches were taken
to further explore the potential usefulness of liposomes for BNCT: 1) An alternative tumor
model; the SCCVII mouse squamous cell carcinoma, was used to see whether there was
any improvement of boron uptake and uniformity in the tumor and 2) a modified injection
protocol was used in an attempt to increase the '0B concentration and uniformity of uptake
in the EMT-6 tumor model.
The final chapter summarizes the significance of this thesis and the general concepts
of evaluating boron compounds and recommends considerations for future work.
CHAPTER Two
METHODOLOGY FOR IN VITRO COMPOUND
SCREENING
2-1. Introduction
With the understanding of the significance of new boron compounds and the
development in drug technology such as drug delivery and targeting, there have been many
studies for synthesizing new boron compounds [47-51]. These new compounds are tested
in cell culture for toxicity and uptake [52-55], or may instead be directly evaluated in small
animals [44, 56-60]. A simple and efficient in vitro study could play an important role in
identifying the most promising constructs especially when several variations of a particular
compound are synthesized and must be evaluated for BNCT. Besides, in vitro studies can
minimize the quantity of compound needed as well as time and cost compared with in vivo
systems [61]. For example, a few milligrams of compound would be required for in vitro
studies, whereas in vivo studies typically need several grams of compound. In vitro
screening to test the efficacy can derive information that is useful in designing further
studies. This chapter describes the development of a methodology for in vitro compound
screening.
A new arrangement for cell irradiations had to be designed and optimized in the
vertical beam line of the thermal neutron beam at the MITR-II since cell irradiations to
investigate the effects of different boron compounds had not previously been performed at
the MITR-II. At Brookhaven National Laboratory, in vitro experiments for BNCT were
carried out at the Brookhaven Medical Research Reactor (BMRR) [52]. In these
experiments, single cell suspensions were placed in small vials and rotated during
irradiation to uniformly administer neutron fluence [62]. However, because the BMRR had
a horizontal beam channel, this layout was not suited to the vertical geometry of the MITR-
II. The thermal neutron beam has been used for BNCT studies where small animals are
irradiated in a removable shielding box that is part of the beam line shutter [26, 63].
Irradiation jigs for both cell culture flasks and well plates were designed and constructed to
fit the configured shielding box so that cells could be reproducibly irradiated with the
desired neutron fluence.
In this method development, the SCCVII mouse squamous cell carcinoma cell line
was used as a head and neck cancer model but the method described can be adapted for any
cell line. Most head and neck cancers are squamous cell carcinomas, originating from the
mucosal lining of those regions. Tobacco use and alcohol consumption are the major risk
factors for head and neck cancer [64]. The five-year survival rate is about 40 % [65].
Patients with early stage disease are often successfully treated with surgery combined with
radiation therapy and chemotherapy. However, cure rates with conventional treatment have
remained poor for patients with advanced stage disease [66]. Moreover, since these tumors
are located around sensitive organs, such as the central nervous system, oral mucosa, and
skin, a novel and targeted therapy is important to treat head and neck cancer. Therefore, the
selective targeting ability as well as the high-LET dose from BNCT could be beneficial for
the treatment of head and neck tumors.
Assays
Clonogenic and colorimetric assays were devised to detect and measure cell damage
from the radiation exposure in the presence of newly developed boron compounds,
especially for low molecular weight compounds, using only the limited quantities (a few
milligrams of '01B) which chemists can practically make available for testing in the early
stage of compound development. The clonogenic assay or colony forming assay, is a
widely-used, accepted standard method to measure the radiosensitivity of cells. Tumor cells
survive when they can proliferate indefinitely and form a large colony from a single cell.
After the irradiation, cells may still be viable and able to produce proteins, synthesize DNA,
and even divide once or twice. However, if it cannot reproduce indefinitely, it is considered
dead [67]. Therefore, for the clonogenic assay, individual tumor cells are separated and
plated to grow into a colony consisting of at least 50 cells, which is defined as having
reproductive integrity and represents cell survival [68]. This clonogenic assay will be used
as a standard method to determine the radiobiological effectiveness of compounds in the
definitive in vitro compound evaluation.
A colorimetric assay is generally used to determine the cytotoxic effect of a drug or
radiation on the viability and proliferation of the cell. This endpoint is an alternative that is
distinctly different from the reproductive integrity measured by the clonogenic assay. The
tetrazolium salt, such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), is reduced by enzymatic activity in viable cells into colored formazan crystals. The
amount of color produced is proportional to the number of viable cells and can be
quantified using a microplate reader that measures the intensity of transmitted light at a
particular wavelength [69, 70]. This colorimetric assay was used as an initial testing to
facilitate a simpler and more efficient method for determining chemical toxicity and
relative intracellular uptake of boron compounds using only a small quantity (less than a
milligram of l°B).
In order to determine relative intracellular accumulation of a test compound, boric
acid and BPA were used as reference compounds because the intracellular accumulation of
these compounds is well known. Boric acid is a very useful reference compound for
radiobiological experiments because it is transported into cells only by diffusion and
distributes uniformly inside cells in vitro at the same concentration as present in the growth
medium (i.e. approximately 1:1 intracellular/extracellular accumulation ratio) [71]. More
preferential intraceullular accumulation was shown with BPA for tumor cells because BPA
is transported into cells through the cell membrane by the amino acid transport system [28].
For example, the intracellular/extracellular accumulation ratio of BPA for a rat brain tumor
cell line, the 9L gliosarcoma, was 3.2 [71, 72]. Even though the boron uptake into the cells
depends on the cell lines, a study to evaluate intracellular/extracellular accumulation ratio
with various tumor cell lines showed BPA preferentially accumulated in the tumor cells
[72]. Thus, BPA was also expected to have a higher intracellular accumulation in the
SCCVII cells used in the studies described here. Cell survival experiments with these
reference compounds (boric acid and BPA) and test compounds give an indirect estimation
of relative intracellular accumulation for a test compound. To demonstrate the in vitro
method, the boronated porphyrin, BOPP, is studied as a test compound.
Cell survival curves
The response of cells to radiation is measured as a function of radiation dose using
clonogenic and colorimetric assays and these results are given as cell survival curves. A
cell survival curve describes the relationship between the radiation dose and the proportion
of surviving cells after the radiation exposure, which is generally represented by plotting
the surviving fraction on a logarithmic scale on the y-coordinate against the radiation dose
on a linear scale on the x-coordinate. The shape of the cell survival curve is different for
radiation with different LET. High-LET radiations produce a cell survival curve that is
almost a straight line on a log-linear plot. Low-LET radiation yields curves with an initial
slope followed by a shoulder region that becomes nearly straight at higher doses [67]. The
shoulder region is generally accepted to represent the ability of cells to repair sub-lethal
damage. Numerous mathematical models have been proposed to describe the shape of cell
survival curves, which are based on the random nature of energy deposition by radiation.
The linear- quadratic model is now most often used to describe the cell survival curve,
assuming that there are two ways to cause cell killing that is presumed to arise from a
double stranded break in the DNA caused by the radiation. The linear component (a)
describes cell killing by a single track of radiation; the quadratic component (03) represents
cell killing by two separate events in the same target.
SF(D) = exp(-caD - flD2) (1)
where SF(D) is the surviving fraction at a certain dose D, and a and P3 are constants.
Biological weighting factors
Different types of radiation produce different levels of biological response for the
same absorbed dose. When radiation is absorbed in a cell or tissue, the energy is deposited
through ionization and excitation along the tracks with a pattern that is characteristic of the
type of radiation involved. Also, when neutrons interact with tissue, neutrons set in motion
a charged particle spectrum that consists of proton, alpha particle, and heavier ions. X- or 7-
rays produce only electrons with a low ionization density; whereas heavier charged
particles (such as protons, alpha particles, and heavier ions such as Li) generate a much
more dense pattern of ionizations. The term linear energy transfer (LET) represents the
ionization density of the radiation. This difference in LET of the radiation governs the
biological effects observed from a given dose of neutrons, protons, and alpha particles
compared with that of low-LET radiations such as X- or y-rays, and electrons [67].
The relative biological effectiveness (RBE) is a practical method to compare the
biological effects of different radiations. The RBE for a test radiation is determined by
comparing the dose of a reference radiation (generally 250 kVp X-rays) that produces the
same biological effect as a dose of test radiation. Thus, for the same biological endpoint,
RBE - Dose from reference radiation (2)
Dose from test radiation
The RBE changes with the type of radiation and its energy, the type of cell or tissue, the
biological endpoint, the radiation dose, the dose rate, and fractionation [67]. In BNCT, the
biological effectiveness of the boron dose from '0lB(n,a)7Li reaction is dependent not only
on these properties but also on the microscopic distribution of boron in tissue that is
characteristic of a given boron compound. An additional term called the compound
biological effectiveness (CBE) factor was introduced to describe the overall biological
effectiveness of the boron neutron capture dose component. The CBE factor is calculated
for a certain endpoint by comparing neutron beam irradiation in the presence of boron
compound with X-ray irradiation [4].
X-ray Dose = [Beam Dose] [Beam RBE] + [Boron Dose][CBE factor] (3)
Present study
This chapter describes the development of the methodology for in vitro compound
screening using the clonogenic and colorimetric assays. The specific goals include
designing and optimizing the cell irradiation facility at the thermal neutron beam in the
MITR-II, measuring dose, irradiating cells, and the determining cell survival curves fitted
with the linear-quadratic model. Cell survival experiments with reference compounds
(boric acid and BPA) and a test compound (BOPP) give an indirect estimation of relative
intracellular accumulation for BOPP. To demonstrate the in vitro method, the boronated
porphyrin, BOPP, is studied as a test compound. To quantitatively analyze the biological
efficacy of a test compound, CBE factors are calculated after determining the beam RBE. A
rigorous analysis of the uncertainty of all measured and derived quantities is included. Also,
the advantages and limitations of the developed method are discussed.
2-2. Materials and methods
2-2-1. Thermal neutron irradiation facility
Figure 2.1. The cross-section view of the MITR-II with the M-011 thermal neutron
irradiation facility directly beneath of the core. (This image is kindly provided by Dr. Kent
Riley.)
The MITR-II has a 5 MW maximum operating power and contains a number of
experimental facilities. The core is comprised of highly enriched uranium fuel elements,
which are cooled and moderated by light water. Neutrons from the core are reflected and
moderated by a heavy water tank below the core, producing a peak thermal neutron flux of
-x10 14 n/cm2-s at 5 MW power. Thermal neutrons are collimated by the surrounding
graphite walls of the beam line. The high intensity of thermal neutrons at the position of the
field delimiter, -5x10 9 n/cm 2-s, and very low photon and fast neutron contamination of the
thermal neutron beam facility, is well suited for preclinical cell culture experiments or
small animal studies and for clinical studies of superficial tumors [26]. The beam is turned
on by first emptying a water tank beneath the D20 reflector. Beam shutters of lead and
neutron-absorbing boral (boronated aluminum) are then opened and a bismuth photon
shield and collimator are move into the beam line together with the shielding box
containing animals or cells. Figure 2.1 illustrates the cross-section view of the MITR-II
with the M-011 thermal neutron irradiation facility directly beneath of the core.
2-2-2. Experimental arrangement at MITR-II
An experimental setup to reproducibly position cell cultures was designed for the
shielding box that is part of the beam line shutter in the M-011 thermal neutron beam of the
MITR-II. This box efficiently absorbs low energy neutrons in the beam producing very
little secondary radiation and helps minimize activation inside the medical room. During
the irradiation, cells are attached to the bottom of the tissue culture flask (clonogenic assay)
or a 96-well plate (colorimetric assay). Platforms to position flasks or 96-well plates in the
shielding box were designed and built. Acrylic plates and nylon bars were used to make the
platform considering practical use, durability, low residual radioactivity after the irradiation,
and light weight due to the vertical position of thermal neutron beam. Also, in order to
minimize the amount of boron compound used for screening, two flasks with smallest
growth area of 12.5 cm 2 or one 96-well microplate (0.37 cm 2 per well, 35.5. cm 2 total) were
employed for each irradiation. Scatterers made of acrylic plate were put around the flasks
or 96-well plates to provide a more uniform dose distribution where cells were placed
during irradiation. Elastic neutron scattering with the hydrogenous plastic will return some
neutrons that would otherwise be lost from the beam.
2-2-3. Dose measurements at MITR-II
Gold foil activation analysis was used to measure thermal neutron flux. Bare gold
foils (12-18 mg, 0.005 cm thick) were positioned on the bottom of flasks containing 1 ml of
growth medium to reproduce the cell irradiation condition, and then irradiated for
approximately 30 minutes. Smaller gold foils (3-4 mg, 0.005 cm thick) were placed at the
bottom of several wells in a 96-well plate and covered with 100 pl of growth medium, and
then irradiated for a similar duration. 197Au reacts with neutrons to form 198Au that emits a
411 keV photon during decay. The 2200 m/s neutron flux was determined from
measurement of 198Au activity on foils using a calibrated high purity germanium detector.
Nitrogen dose from 14N(n,p)14C reactions and 10B dose from loB(n,a)7Li reactions were
determined by multiplying the measured 2200 m/s flux by kerma coefficients of 7.88x10 -12
Gy/cm 2 and 8.66x10 8 Gy/cm 2, respectively.
The dual chamber technique [73] was applied to measure photon and fast neutron (En
> 0.5 eV) absorbed doses. An A-150 tissue-equivalent ionization chamber filled with
tissue-equivalent gas (64.4 % CH 4, 32.4 % CO2, and 3.2 % N2 by partial pressure)
measured the total dose from photons and neutrons. A carbon (graphite) walled ionization
chamber filled with CO 2 gas, which has little response to neutrons, was used to repeatedly
measure the photon dose. The gas flow rate of both chambers was 20 ml/min, and the
voltage was +250 V. During measurements, chambers were positioned in the center of a
flask near the bottom and next to a second flask containing 1 ml of growth medium or in
the middle of a 96-well plate through a hole made for dosimetry. All details of these
dosimetry methods including the dual chamber technique and gold foil analysis are
described elsewhere [73]. Beam monitor counts were recorded and calibrated by these
absorbed dose measurements. Ultimately, these beam monitor counts control beam delivery
during cell irradiations to 1 % precision. Overall uncertainties associated with the
dosimetry are 5 % for thermal neutron, 5 % for photon, and 7 % for boron component [26,
74].
2-2-4. Cell culture conditions
The SCCVII mouse squamous cell carcinoma cell line was generously provided by
Brookhaven National Laboratory. The cells were grown in Dulbecco's Modified Eagle's
Medium (DMEM, Mediatech) supplemented with 10 % fetal bovine serum (SeraCare Life
Science), 1 % 200mM L-glutamine (Mediatech), and 1 % 5,000 I.U./ml penicillin - 5,000
pg/ml streptomycin (Mediatech) at 37 'C in an atmosphere of 5 % CO 2. The cell doubling
time is about 15 hours. The cells were sub-cultured every 5-7 days. To maintain
consistency of cell characteristics, new cells were started from cryogenically preserved
stocks after -24 passages (about 5 months).
2-2-5. Cell counting
Cell numbers were counted using a Z2 Coulter Counter from Beckman Coulter.
When cells suspended in an electrolyte are passed through a small aperture, the counter
detects changes in electrical conductance. The counter displays cell concentration and size
distribution of the counted cells. Five measurements were carried out on 1 ml suspensions
from each flask and averaged to get the final result. Cell numbers measured with the
Coulter Counter were periodically cross-checked with results from manual counting using a
hemocytometer and agreed to within 5 %.
2-2-6. Boron compounds
Boric acid (H3BO 3, 94.56 % IOB enriched) was used as the reference boron
compound that uniformly distributes inside and outside cells [71]. BPA-fructose solution
(p-boronophenylalanine, > 99 % IoB enriched, L-isomer) was prepared as a positive control
that preferentially accumulates inside tumor cells [72].
As a test compound, the boronated porphyrin BOPP (tetrakis-carborane carboxylate
ester of 2,4-bis-(alpha,beta-dihydroxyethyl)-deutero-porphyrin IX, loB enriched) was
dissolved in phosphate-buffered saline (PBS lx) and stored at 4 'C in darkness, because
porphyrins are sensitive to visible light. Experiments with BOPP solution were carried out
under low intensity light [75]. The BOPP was synthesized by Professor Steve B. Kahl from
the University of California, San Francisco and the solutions for testing were kindly
prepared by M.Alejandra Dagrosa from Constituyentes Atomic Center, Argentina.
2-2-7. Boron analysis
The 10B concentration of each boron solution was measured using Prompt Gamma
Neutron Activation Analysis (PGNAA) in the MITR-II. PGNAA detects the 478 keV
photons produced from boron neutron capture reactions in loB [76]. Boron solutions were
diluted into growth medium to make the desired 10B concentration for each experiment. I0B
concentrations of diluted solutions were confirmed with PGNAA. The uncertainty of
measurement is less than 5 %.
2-2-8. Cell irradiation
Two flasks or a 96-well plate were positioned on the platform in the shielding box
(see Figure 2.2) which was placed in the beam line. Cells were irradiated with graded doses
of the thermal neutron beam with and without boron compound in the medium. Boron dose
is calculated with 10B concentration in the growth medium. Based on the beam monitor
counts calibrated by dosimetry measurements, the desired neutron fluence was given with
1 % precision. Also, cells were irradiated with graded doses of X-rays. A Phillips RT250
unit in the MIT Nuclear Science and Engineering Department was used, operating at 250
kVp and 15 mA with 0.4 mm Sn plus 0.25 mm Cu added filtration and a focus-to-target
distance of 23cm. The average X-ray dose rate to the cells at the bottom of the flask was 1.0
Gy/min and this was measured with an air-filled graphite ionization chamber periodically to
check for consistency. The administered doses have an estimated uncertainty of
approximately 3 % based upon calibration precision of the ionization chamber, positioning
errors, and output constancy of the machine.
2-2-9. Fitting survival data to the linear-quadratic model
The linear-quadratic model has been used to fit survival data from the clonogenic and
colorimetric assay cell survival experiments, by means of the TableCurve 2D software,
version 5.01 (SYSTAT Software Inc., 2002). This program uses an automated curve fitting
process to find the ideal model using weighted, least square curve-fitting. Data points were
weighted with the inverse square of the standard deviation. The coefficients of a and P3 with
the standard errors from the linear-quadratic equation, SF(D) = exp(-aD - flD2) were
obtained, using the coefficient of determination, R2, as a measure of the goodness-of-fit.
Also, chi-square statistics were calculated to verify the goodness-of-fit [77, 78].
2-2-10. Calculations of RBE and CBE
The fitted linear-quadratic equations were used to interpolate the doses of X-ray and
neutron beam corresponding to a specified surviving fraction. Surviving fractions of 0.02
for the clonogenic assay and 0.2 for the MTT assay were chosen because those were
suitable ranges for each assay based on results of X-ray irradiations. The RBE of the
thermal neutron beam was then obtained using equation (2) in 2-1. CBE values for the
boron compounds were obtained using equation (3) in 2-1 after determining the beam RBE
and the neutron beam and boron dose components for a given surviving fraction.
2-2-11. Uncertainty analysis
In order to analyze uncertainties of RBE and CBE, total uncertainties of interpolated
doses were estimated by propagating the uncertainties from curve fitting and dose
measurement. The fitting uncertainty of dose was determined using the standard errors of
the fitting-coefficients, a and J3, and these fitting uncertainties were averaged for each assay
(2.8 % for clonogenic assay and 3.5 % for MTT assay). The estimated uncertainty in the
dose measurement for both clonogenic and MTT assay was 3 % for X-rays, 5 % for the
neutron beam, and 7 % for boron, which includes 5 % uncertainty in the boron
concentration measurement.
The estimated uncertainty in the neutron beam RBE was calculated using error
propagation [77, 78] associated with the X-ray and neutron beam endpoint doses.
TRBE = RBE x 1O'X-rays Dose 2 + Neutron beam Dose 2 (4)(X -ray Dose) (Neutron beam Dose
Next, the uncertainty of CBE for each boron compound was obtained using error
propagation through all components of the CBE equation as follows:
BEX-ray Dose-( Neutron beam DosexRBE) 2 ± Boron Dose 20 "CBE  = CBE x +...
X - ray Dose - (Neutron beam Dose x RBE)) K Boron Dose)
0 X -ray Dose-( Neutron beam DosexRBE)
== U-ray Dose + 0( Neutron beam Dosex RBE) (5)
( Neutron beam Dosex RBE) =
(Neutron beam Dose x RBE) x ONeutron beam Dose + 7RBE 2(eN•eutron beam Dose) RBE
2-3. Clonogenic assay
2-3-1. Experimental arrangement and dosimetry
The initial arrangement shown in Figure 2.2 used two T12.5 flasks completely filled
with growth medium turned upside down. This arrangement positioned cells that were
attached to the bottom of the flasks closer to the thermal neutron beam and provided a
simple geometry for dosimetry. However, to fill a flask completely, almost 43 ml of
medium was needed and so this would require a large amount of compound. For example, a
boron solution with a concentration of 10 gg 10B/ml would require 430 [tg loB in one flask.
Cells must be irradiated with several graded doses of neutrons and at least a few milligrams
of loB compound would be required for this test, which may exceed the quantity available.
Such a large amount of new compound may not be practical for preliminary cell culture
studies.
Figure 2.2. Initial arrangement with inverted T12.5 flasks which are completely filled with
growth medium for cell irradiations with the thermal neutron beam at MITR-II.
An optimized new arrangement for the clonogenic assay was with two T12.5 flasks
in the normal position, each containing 1 ml of growth medium. Scatterers made of acrylic
plate surround the flasks, and this also served to guide flasks into the same position for
every experiment. Beneath the platform, a thick scatterer was used to help backscatter
useful thermal neutrons and create a more uniform dose profile over all the cells. This setup
requires less than a milligram of l'oB. Figure 2.3 shows the schematic view of the
experiment setup for the clonogenic assay.
The thermal neutron flux normalized to the reactor operating at 5 MW of 8.5 (+ 0.4)
xl0 9 n/cm 2-s, was determined from the average of several gold foil measurements at
different positions through the bottom of two flasks. The nitrogen and boron capture dose
rates were determined as 14.2 ± 0.7 cGy/min and 4.4 + 0.3 cGy/min per gg loB/ml,
respectively, assuming a nitrogen concentration of 3.5 %. Dual ionization chamber
measurements determined a photon absorbed dose rate of 26.9 ± 1.3 cGy/min with
negligible fast neutron contamination in the thermal neutron beam. With 10 gl'oB/ml
concentration, the boron capture dose is 52 % of the total absorbed dose (Table 2.1).
Estimated uncertainties for dose measurement were 5 % for the nitrogen capture dose, 5 %
for photon dose, and 7 % for boron dose which includes uncertainties of thermal neutron
flux measurement and boron concentration measurement.
Table 2.1. The absorbed dose rates for cells in flasks containing 1 ml of medium
normalized to 5 MW, the full power of the reactor.
Thermal neutron flux Absorbed dose rate (cGy/min)
2 Boron(n/cm -s) Nitrogen Fast neutron Photon (per g B /m)
8.5 (± 0.4) x 109 14.2 ± 0.7 <0.1 26.9 ± 1.3 4.4+ 0.3
< Side view >
< Top view >
Figure 2.3. Schematic view of the setup to carry out the thermal neutron irradiation for
clonogenic assay in the MITR-II. Two T12.5 flasks were irradiated simultaneously in the
15 cm diameter circular field. Plastic scatterers were positioned to produce more uniform
irradiation of the flasks.
2-3-2. Cell survival experiment
SCCVII cells (-3x10 5) were plated into each T12.5 flask (growth area of 12.5 cm 2)
with 5 ml of growth medium one day before the irradiation. To remove the trypsin from the
cell suspension and increase the plating efficiency, cell suspensions were centrifuged and
Shielding box
the supernatant removed. Then, cells were resuspended with new growth medium and
plated in the flask. Flasks were incubated overnight (approximately 20 hours) to allow cells
to attach to the bottom. Two hours before the irradiation, growth medium was replaced with
medium containing the desired amount of boron. Two flasks were irradiated together with
graded doses of thermal neutron beam. For X-ray irradiations, cells were plated in T25
flasks (growth area of 25 cm2) with 5 ml of growth medium and incubated overnight to
allow attachment. Then, cells in T25 flasks were irradiated with graded doses of X-rays.
Control flasks which received no irradiation were kept in the thermal neutron beam control
room at the MITR-II or in the X-ray machine room during the experiment.
After the irradiation, cells were trypsinized with 0.25 % trypsin containing 0.1 %
EDTA for 3 minutes in the incubator (37 'C, 5 % CO 2), and then resuspended with growth
medium. After cells for each flask were counted 5 times with the Coulter Counter, a known
number of cells was plated into 100x20 mm Petri dishes. Five replicate dishes were used
for each flask. The medium was changed at 5 days after cells were plated. After 7-10 days,
medium was removed, and the colonies were fixed and stained with 1 % methylene blue in
95 % ethanol for 5-10 minutes. Dishes were washed with flowing water and dried at room
temperature. Colonies containing more than 50 cells were counted. This procedure is
briefly illustrated in Figure 2.4.
The surviving fraction (SF) was calculated as:
number of coloniesSF (%) =
number of seeded cell x (plating efficiency/1 00)
The plating efficiency (PE) from non-irradiated control plate is determined from the
following formula:
PE(%) number of colonies XPE(%  = × 1O00
number of seeded cell
The plating efficiency varies due to experimental or cell variability. Thus, every experiment
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Figure 2.4. Outline of experimental procedure for the colony forming assay [67]. Cells are
irradiated with graded dose of radiation (thermal neutrons or X-rays) and resuspended in
the growth medium by trypsinization. Known number of cells are plated into Petri dishes
and incubated for 7-10 days. The numbers of colonies are counted and used for calculation
of surviving fractions with the plating efficiency determined from non-irradiated control
plate.
2-3-3. Survival curve
Figure 2.5 presents the fitted survival curves using the clonogenic assay for SCCVII
cells irradiated with 250 kVp X-rays, the thermal neutron beam, and the thermal neutron
beam in the presence of 5 and 10 gg 10B/ml boric acid. The survival data points of neutron
beam irradiation with 2.3 jg 10B/ml BPA are also shown in Figure 2.5. The x-axis shows
total absorbed dose which is the sum of the beam and boron doses. Boron doses were
calculated from the measured boron concentration in the medium. The data represent four
independent X-ray and neutron beam irradiation experiments and a single experiment with
each boron compound. Error bars indicate the relative errors with error propagation through
the whole procedure (from cell counting to colony counting) of five replicate dishes.
Average plating efficiencies were 44 % for X-ray experiments and 20 % for neutron
experiments. This lower plating efficiency in the neutron experiments was attributed to the
cells being left at room temperature for longer period during the irradiation in the MITR-II.
With X-rays, the surviving fraction slowly decreased as dose increased. Thermal
neutron beam irradiation produced a greater decrease in survival fraction than X-rays, but
the survival curves of X-ray and neutron beam were relatively similar due to the high
percentage of photon dose component (65 %) in the neutron beam. Neutron beam
irradiation in the presence of boron compound clearly produced additional cell killing effect.
Greater cell killing was observed with an increased boron concentration from boric acid.
Only the survival data points with BPA are shown in Figure 2.5 without a fitted curve due
to the limited number of data points. Still, the points show that the cell killing effect of
BPA is comparable to twice the concentration of boric acid (5 gg l'oB/ml) in the low dose
range.
Table 2.2 lists the fitting coefficients (a and 03) and the goodness-of-fit (R2 and )2) of
the survival curves fitted using the linear-quadratic model. Curves of X-rays, neutron beam,
and 5 gg l'oB/ml boric acid had an initial shoulder region; while curves of 10 jg '0B/ml
boric acid showed straight lines with 3 = 0. The goodness-of-fit values of R2 and P
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Figure 2.5. Survival curves fitted using the linear-quadratic model for SCCVII cells
irradiated with 250 kVp X-rays, the thermal neutron beam, and the thermal neutron beam in
the presence of 5 and 10 [tg loB/ml boric acid (BA) and survival data points for 2.3 tg
1oB/ml BPA using the clonogenic assay. Results are expressed as the average + uncertainty
for surviving fractions and error bars are shown when these are larger than the symbols.
Table 2.2. Fitting coefficients (a and 13) for the linear-quadratic model and goodness-of-fit
(R2 and x2) for X-rays, the neutron beam, the neutron beam with 5 and 10 jg oB/ml boric
acid (BA) when using the clonogenic assay.
Radiation SF = exp (- aD - 13D 2) Goodness-of-fit 2Radiation 2 2X 13 R' X
0.0027
X-rays 0.163 ± 0.036 0.076 ± 0.007 0.9971 .)(p=1.0)
0.0011
Neutron beam (N) 0.338 + 0.031 0.068 ± 0.007 0.9984 .0(p=1.0)
0.0003
N + 5 jg 10B/ml BA 0.703 ± 0.030 0.074 + 0.008 0.9990 .0(p=1.0)
0.9546
N + 10 g I10B/ml BA 1.351 + 0.005 0 0.9998 .9(p=0.8122)
2-3-4. Toxicity
To ensure that the results observed in Figure 2.5 are due primarily to radiation effects,
a toxicity study was performed under similar experimental conditions. An experiment was
performed using boric acid to determine whether chemical toxicity during the 24 hour
incubation period before irradiation contributed to the cell kill observed during clonogenic
assay cell survival experiments. Cells were exposed to 40 pg 'oB/ml boric acid solution for
24 hours. Before irradiation with thermal neutrons, the cells were washed and new growth
medium was added to completely remove boric acid during irradiation. Control cells that
had no boric acid showed 22 % plating efficiency and cells exposed to 40 pg 'oB/ml boric
acid for 24 hours had a plating efficiency of 16 %. This lower plating efficiency may be due
to the chemical toxicity of boric acid. Surviving fractions for this test were not considered
significantly different for the two groups relative to the anticipated radiation damage that
will be induced by the additional boron present in the cell during thermal neutron beam
irradiations (Figure 2.6). This implies that chemical toxicity itself does not affect the cell
response to the radiation for the clonogenic assay and the effect of chemical toxicity was
incorporated into the plating efficiency.
2-3-5. Calculation of RBE and CBE with uncertainty analysis
Table 2.3 shows the doses with uncertainties at surviving fraction of 0.02 for X-rays,
the neutron beam, and the neutron beam in the presence of boric acid. A surviving fraction
of 0.02 was chosen since the clonogenic assay has a large dynamic range for measuring
survival that can span three to four logs (10- -10-4) . The values for the beam RBE and the
CBE factor of boric acid with estimated uncertainties are also presented in Table 2.3. Total
uncertainties on the interpolated dose at the endpoint were estimated to be 4 % for X-rays,
5.7 % for the neutron beam, 7.5 % for boron using the clonogenic assay.
The beam RBE of the MITR-II was 1.1 ± 0.1 for SCCVII cells at 0.02 surviving
fraction. This beam RBE value is close to 1 due to the high proportion of photon dose
component (- 65 %) in the thermal neutron beam. The CBE values for boric acid were 2.4
± 0.3 for 5 gg loB/ml and 3.1 ± 0.3 for 10 gg loB/ml. The CBE value appears to increase
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Figure 2.6. Survival curves fitted using the linear-quadratic model for SCCVII cells
irradiated with the thermal neutron beam using the clonogenic assay. One group of cells
received no pre-treatment with boric acid; the other group of cells were exposed to 40 tg
10B/ml boric acid for 24 hours, then washed free of the boric acid. No boron was present
during irradiations.
Table 2.3. Interpolated doses and RBE/CBE at surviving fraction of 0.02 for X-rays, the
neutron beam, the neutron beam in the presence of 5 and 10 Rg '0B/ml boric acid (BA)
using the clonogenic assay and SCCVII cells.
Radiation Dose (Gy) RBE/CBE
X-rays 6.2 + 0.3
Neutron beam (N) 5.5 ± 0.3 1.1 ± 0.1
N + 5 jg 'lB/ml BA 3.9 ± 0.3 2.4 ± 0.3
N + 10 gg 'oB/ml BA 2.9 ± 0.2 3.1 ± 0.3
2-4. Colorimetric assay
2-4-1. Experimental arrangement and dosimetry
A 96-well plate was prepared for neutron irradiations without using all outermost
wells because gold foil measurements showed that comer wells have approximately 25 %
lower thermal neutron flux than those in the middle. As with the flasks, a scatterer made of
acrylic plate was put around the 96-well plate, which also helped to keep the plates in the
same position for every experiment. In addition, a thick scatterer was placed underneath the
plate with a hole in the center to improve uniformity of the thermal neutron flux in the outer
wells. Figure 2.7 illustrates the arrangement of 96-well plate for cell irradiations.
The average thermal neutron flux (excluding the edge wells) was 7.7 (± 0.4) x10 9
n/cm 2-s, and faas again trivial (< 0.1 cGy/min). With 10 lg
0oB/ml concentration, the boron capture dose produces 46 % of the total absorbed dose
(Table 2.4). Estimated uncertainties were 5 % for the nitrogen capture dose, 5 % for photon
dose, and 7 % for boron dose.
Table 2.4. The absorbed dose rates for cells in a 96-well plate containing 100 gl of medium
in each well normalized to 5 MW reactor power.
Thermal neutron flux Absorbed dose rate (cGy/min)
(n/cm2-s) Nitrogen Fast neutron Photon Boron
(per lg 'OB /ml)
7.7 (± 0.4) x 109 12.8 ± 0.6 < 0.1 34.4 ± 1.7 4.0 + 0.3
Figure 2.7. Schematic view of the setup to carry out thermal neutron irradiations for the
colorimetric assay in the MITR-II. A 96-well plate was irradiated in the 15 cm diameter
circular field. Plastic scatterers were positioned to produce more uniform irradiation of the
plate. Only the shaded wells in the 96-well plate were used for experiments.
2-4-2. Preliminary study
The colorimetric assays are based on the conversion of tetrazolium salt to a colored
product by enzymatic activity of viable cells. The amount of color produced, which is
directly proportional to the number of viable cells, can be measured using a microplate
reader that measures the optical density in each well, using the appropriate light wavelength.
The first colorimetric assay evaluated was based on a reagent known as WST-1. The WST-
1, tetrazolium salt (4-[3-(4-lodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene
disulfonate), is cleaved to form a formazan dye by a mitochondrial enzyme in direct
proportion to the number of viable cells present. An assay kit is available including a WST-
1 reagent (Roche Applied Science). Due to simpler processing step and higher sensitivity,
the WST-1 assay has advantages over other cell proliferation agents for some applications:
e.g. those that only measure chemical toxicity [79]. However, numerous preliminary
experiments showed that this assay is too sensitive for use in our radiation response assay.
To compare OD of non-irradiated control cells with that of irradiated cells showing
measurable radiation damage, a practical number of cells have to be plated in each well
allowing 4-5 days of growth time after irradiation. For example, with WST-1, OD numbers
of the control cells after 5 days of growth time were mostly out of reading range (OD > 3)
even though only 100 cells were initially plated in each well. Due to this limitation, an
alternative colorimetric assay was evaluated: the more generally used MTT colorimetric
assay.
The MTT tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, is reduced into purple formazan crystals. The MTT assay kit (Roche Applied
Science) available includes a MTT labeling reagent and a solubilization solution. Figure 2.8
shows the average OD numbers using WST-1 and MTT assays as a function of SCCVII
cells initially plated in each well. These numbers were measured right after cells were
plated and no irradiation was involved. Higher OD numbers from the WST-1 assay were
measured for increasing numbers of cells in each well than those from the MTT assay. This
means that with the MTT assay each well can contain more cells and still have an OD
reading in the measurable range.
In order to determine the growth time, preliminary experiments were performed with
varying growth times from 3 to 6 days, and the optimum was found to be 5 days. Over a 5
day period, however, depletion of nutrients in the medium could lead to sub-optimal growth.
An additional preliminary study (Figure 2.9) was carried out to evaluate the OD after 5
days growth as a function of cells plated in each well and to determine the effect of
changing the medium during the incubation period. Since the colorimetric assays are based
on cell growth differences between non-irradiated control cells and irradiated cells, the loss
of cells during the procedure of pipetting for medium changing could be a potential
problem. OD numbers were measured at 5 days with and without a medium change 3 days
after cell plating. Cells with medium change produced slightly higher average OD number
than cells without medium change, especially for higher cell numbers initially plated. This
indicates that OD numbers decrease more due to lack of nutritious medium than due to
possible cell loss during medium change. In Figure 2.9, a cell density of 500-1000
cells/well maximizes cell growth after the 5 day period selected to use for the MTT assay.
This may result from further medium depletion or confluence of cells at the higher cell
densities. Thus, our protocol specifies a cell density of 500 cells/well and the addition of
medium 3 days after cell plating to feed the cells and to avoid potential differences in their
subsequent growth. Also, all 96-well plates should have blank wells containing only
medium or medium with boron compound present to obtain an accurate blank OD number,
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Figure 2.8. Average optical density (OD) numbers as a function of SCCVII cell number
plated in one well using WST-1 and MTT assays. These OD numbers were measured right








Figure 2.9. Average OD using the MTT assay as a function of SCCVII cells plated initially
in each well. OD numbers were measured right after cell plating or 5 days after cell plating.
Also, OD numbers were compared with medium changing at 3 days after plating or without
medium changing. Arrows indicate the cell numbers in well (500 cells/well) for our
protocol. Lines are drawn connecting the data to help guide the eye.
2-4-3. Cell survival experiment
A single cell suspension of SCCVII cells was prepared and the cell density was
counted with the Coulter Counter. A total of 500 cells were plated in each well of the 96-
well plate with 100 gl growth medium. This plating density of cells, 500 cells/well, was
determined by preliminary experiments to give a useful range of OD. For neutron beam
irradiation with boron compound, cells were plated in growth medium containing boron
compound at the desired boron concentration. Then, plates were incubated overnight (-20
hours) to allow the cells to attach to the bottom of well. The 96-well plate was then
irradiated with graded doses of thermal neutron beam or X-rays. Control plates which
100 500 1000 10000
SCCVII cells plated (numberlwell)
received no irradiation were kept in the thermal neutron beam control room at the MITR-II
or in the X-ray machine room during the experiment.
To demonstrate the study for determining efficacy of a test compound, cells were
plated with boric acid for a reference, BPA for a positive control, and BOPP for a test
compound. Each plate used the same boron concentration for these three boron compounds
(see Figure 2.10 as an example). Boron concentrations of approximately 5, 10, 20, or 40 pg
10B/ml were used in the presence or absence (blanks wells) of cells, with one plate for each
concentration in each plate. Separate plates were irradiated with different neutron exposure
times to produce total absorbed doses of approximately 1.7 and 3.3 Gy.
Figure 2.10. Example of experiment design in a 96-well plate for testing a new compound.
Here, BOPP is the compound being tested. 10 wells contain each compound-only solution
as blank (without cells) and another 10 wells contain cells together with the compound at
the same concentration.
After the irradiation, plates were returned to the 37 'C incubator. After two days, 100
[l of medium was added to each well to supply enough nutrients to the growing cells. After
two more days, 100 jl of medium was removed from each well being careful not to touch
the bottom of the well to avoid removing any cells. Then, 10 al of MTT reagent was added
to each well. After 4 hours of incubation, 100 il of solubilization solution was added to
each well, and the plates were incubated again for -23 hours. Finally, OD numbers were
measured against a background control as blank using a microplate reader (Figure 2.11,
Bio-TeK Instrument, Inc.) at 570 nm wavelength. The reference wavelength is 660 nm.
The survival was expressed as the fractional OD, which is equivalent to surviving
fraction from the clonogenic assay, by the relative percentage of OD compared to non-
irradiated control cells [80].
Fractional OD ODirradiated - ODblank (irradiated)Fractional 0OD = ODcontrol - OD1blank(control)
Blank means that there are no cells, but there is medium alone or medium containing boron
compound in the well.
Figure 2.11. Microplate reader (EL800, Bio-Tek Instrument, Inc.) and a 96-well plate.
2-4-4. Survival curves
Figure 2.12 shows fitted survival curves for SCCVII cells irradiated with X-rays,
with the neutron beam, and with the thermal neutron beam in the presence of different
boron concentrations of boric acid, BPA, and BOPP with the measured boron
concentrations shown in the graphs. The x-axis shows total absorbed dose which is the sum
of the beam and boron doses. Boron doses were calculated from the measured boron
concentration in the medium. The data represent three independent X-ray and neutron beam
only experiments and a single experiment for the boron compound. Error bars indicate the
relative errors with error propagation from standard deviations of OD numbers of 10-20
wells.
Like the clonogenic assay, survival curves of X-rays and the neutron beam were
close due to the high fraction of photon dose component (73 %) in the neutron beam.
Neutron beam irradiations in the presence of boric acid and BPA clearly produced an
additional cell killing effect. Cell survival was expected to decrease as a function of
increasing boron concentration due to the increasing percentage of high-LET radiation
component. Boric acid showed that cell survival decreased as boron concentration
increased up to 20 tg '0B/ml. Boric acid with 40 [ig 10B/ml produced large uncertainty
because of too much cell killing from chemical toxicity. Figure 2.13 presents primary data,
average OD numbers, as a function of total absorbed dose (Gy) for different boron
concentrations of boric acid. These primary data were used to obtain the fractional OD by
normalizing to the average OD of non-irradiated control (0 Gy) cells. Due to the chemical
toxicity, average ODs of control cells decreased and those of irradiated cells were in the
very low OD range which is close to background blank OD. This condition produced large
estimated uncertainties for the higher boron concentrations of boric acid.
In irradiations with BPA, cell survival decreased as boron concentration increased up
to 10 jg 10B/ml. However, with higher boron concentrations of 20 and 40 tg 10B/ml, cell
survivals were similar to those of lower boron concentrations due to the overestimations of
survivals caused by excessive cell kill from high boron concentrations. Due to the large
uncertainty in BOPP experiments because of chemical toxicity, it is difficult to see how
much effect different boron concentrations of BOPP produced to cells. The primary data for
BOPP are not shown here, but a trend of decreased average OD with increasing boron
concentration similar to that shown in boric acid (Figure 2.13) was observed.
The fitting coefficients of linear-quadratic equations and the goodness-of-fit for each
curve are given in Tables 2.5 to 2.8. Curves of X-rays and the neutron beam showed an
initial shoulder region; on the other hand, curves of neutron beam irradiations with all
boron compounds showed straight lines with 3 = 0. The values of R2 and P (probability)
from X2 test were close to 1.0, demonstrating that survival curves fit the linear quadratic
model well. None of the boron compounds with approximately 20 jtg loB/ml fit perfectly
because of overestimated survivals for higher dose points due to either chemical toxicity or
the excessive cell killing.
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Figure 2.12. Survival curves fitted with the linear-quadratic model using the MTT ssay for
SCCVII cells irradiated with 250 kVp X-rays, the thermal neutron beam, and the thermal
neutron beam in the presence of boric acid (BA), BPA, and BOPP with increasing boron
concentrations. The fractional OD of cells is plotted on a log scale against total absorbed
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Figure 2.13. Average OD measured after 5 days of growth time using the MTT assay as a
function of total absorbed dose (Gy) for the SCCVII cells irradiated with the neutron beam
in the presence of boric acid (BA) at different boron concentrations. Lines are drawn
connecting the data to help guide the eye.
Table 2.5. Fitting coefficients (a and 03) for the linear-quadratic model and goodness-of-fit
(R2 and 2) for X-rays and neutron beam irradiations using the MTT assay.
Radiation SF = exp (- aD -pD 2) Goodness-of-fitRadiation a p R2 2
0.0028X-rays 0.128 ± 0.032 0.031 ± 0.006 0.9952
(p=l.0)
0.0009Neutron beam (N) 0.162 + 0.017 0.045 + 0.004 0.9994
(p= .0)
Table 2.6. Fitting coefficients (a and P) for the linear-quadratic model and goodness-of-fit
(R2 and x2) for neutron beam irradiations with 6, 11, 21, and 40 [ag 'oB/ml boric acid (BA)
using the MTT assay.
Radiation SF = exp (- aD - D2) Goodness-of-fit
a 13 R
0.0078N + 6 jlg 'OB/ml BA 0.585 + 0.178 0 0.9946 (p=0.9998)
0.0062N + 11 ig loB/ml BA 0.770 + 0.041 0 0.9736 (p=0.9999)
0.6581N + 21 ig 'lB/ml BA 0.930 ± 0.111 0 0.9171 (p=0.8830)
N + 40 jlg '0B/ml BA 0.697 + 0.012 0 0.9979 0.0039(p=0.9999)
Table 2.7. Fitting coefficients (a and P) for the linear-quadratic model and goodness-of-fit
(R2 and x) for neutron beam irradiations with 5, 9, 20, and 40 jlg '0B/ml BPA using the
MTT assay.
Radiaion SF = exp (- aD - D2 ) Goodness-of-fit
a 1 R2  )2
0.0010N + 5 jg l'B/ml BPA 0.764 ± 0.014 0 0.9991 0.0010(p=0.9999)
0.0007N + 9 gg o0B/ml BPA 0.888 ± 0.013 0 0.9990 0.0007
(p= 1.0)
N + 20 jg l'B/ml BPA 0.843 ± 0.054 0 0.9556 0.5744(p=0.9023)
0.0016N + 40 gLg 'B/ml BPA 0.784 + 0.009 0 0.9988 0.0016
(p= 1.0)
Table 2.8. Fitting coefficients (a and P) for the linear-quadratic model and goodness-of-fit
(R2 and x2) for neutron beam irradiations with 3, 9, 19, and 41 glg '0B/ml BOPP using the
MTT assay.
SF = exp (- aD - O3D 2) Goodness-of-fitRadiation 2
a1 RE  2
0.0077N + 3 jg 'lB/ml BOPP 0.483 ± 0.021 0 0.9958 0.0077(p=0.9998)
N + 9 pg l'B/ml BOPP 0.389 ± 0.001 0 0.9999 0.00001
(p=1.0)
0.3484N + 19 ig 'OB/ml BOPP 0.517 ± 0.076 0 0.6359 0.3484
(p=0.9507)
N + 41 [lg 'OB/ml BOPP 0.652 0.013 0 0.99930.0052
(p=0.9999)
2-4-5. Toxicity
To investigate further the large uncertainty in the survival curves for boric acid and
BOPP using the MTT assay, the chemical toxicity of these two boron compounds was
determined by OD numbers for SCCVII cells incubating with increased boron
concentrations for 5 days without any irradiation involved. Figure 2.14 illustrates that the
toxicity of boric acid and BOPP increases as the boron concentration increases. This
explains why the observed OD numbers for the non-irradiated control cells with boric acid
and BOPP were very low after 5 days of growth time (see Figure 2.13). Five days
incubation time was necessary to allow measurable growth (OD) in the irradiated cells. OD
numbers of a blank reference of BOPP solution (without cells) show a slight increase as the
boron concentration increased (Figure 2.14). OD numbers of cells in higher boron
concentrations of boric acid or BOPP (40 [ig l'oB/ml) are very low and similar to the OD
number of the blank, compound-only solution. This is the reason the survival fractions for
higher concentrations of boric acid and BOPP had very large uncertainty and were
overestimated: even without irradiation there was very little cell growth due to the chemical
toxicity, and thus, very little OD signal remained to measure the radiation effects. This
chemical toxicity information was taken account into surviving curves when normalizing
average OD numbers of irradiated cells with those of non-irradiated cells.
Figure 2.14. Average OD numbers for SCCVII cells using the MTT assay as a function of
boron concentration with boric acid (BA), and BOPP measured 5 days after cell plating.
OD numbers were measured for wells containing cells in boron solution or for wells
containing only boron solution. Lines are drawn connecting the data to help guide the eye.
2-4-6. Calculation of RBE and CBE with uncertainty analysis
Tables 2.9 to 2.12 show the doses with estimated uncertainties at surviving fraction
of 0.2 for X-rays, neutron beam, and neutron beam in the presence of boron compound. A
surviving fraction of 0.2 was chosen since the MTT assay could measure only fractional
survivals in the range of the first two logs (SF > 0.01). The values for the RBE of the
neutron beam and the CBE factor of each boron compound with estimated uncertainty are
also presented in these tables. Total uncertainties of 4.6 % for X-rays dose, 6.1 % for
neutron beam dose, and 7.8 % for boron dose were estimated with the MTT assay. The
beam RBE was 1.2 + 0.1 for SCCVII cells at surviving fraction of 0.2. This RBE value is
similar to that derived from the clonogenic assay and is close to 1 due to the high fraction
of photon dose (73 %) in the neutron beam.
The uncertainties determined by combining the averaged fitting uncertainty together
with dose measurement uncertainty do not accurately represent the uncertainties for the
points where cell killing is too high due to either chemical toxicity or high boron capture
reaction. The low CBE value at 40 tg l0B/ml from boric acid is due to overestimated
survival resulting from the high chemical toxicity. For 20 and 40 -g 10B/ml of BPA, the
CBE factors were lower because of excessive cell killing. The test compound, BOPP,
showed low CBE values at high boron concentration from 10 to 40 jg '0B/ml since the
chemical toxicity is dominant to cell killing. These conditions identify a useful boron
concentration, 5-10 gg '0lB/ml, for in vitro evaluation. The derived results with
underestimated uncertainty are not statistically meaningful, so they are shaded in Tables
2.10 to 2.12.
Table 2.9. Interpolated doses and RBE at surviving fraction of 0.2 for X-rays, the neutron
beam using the MTT assay.
Radiation Dose (Gy) RBE
X-rays 5.4 ± 0.3
Neutron beam (N) 4.5 ± 0.3 1.2 + 0.1
Table 2.10. Interpolated doses and CBE at surviving fraction of 0.2 for the neutron beam
with different concentrations of BA using the MTT assay. Shaded results have uncertainties
that are underestimated due to excessive cell killing and they are not considered statistically
meaningful.
Radiation Dose (Gy) CBE
N + 6 gg l0 B/ml BA 2.8 + 0.2 3.5 + 0.5
N + 11 gg 10 B/ml BA 2.1 + 0.1 4.1 ± 0.4
N + 21 gig 10 B/ml BA 1.7 ± 0.1 4.2 ± 0.4
Table 2.11. Interpolated doses and CBE at surviving fraction of 0.2 for the neutron beam
with different concentrations of BPA using the MTT assay. Shaded results have
uncertainties that are underestimated due to excessive cell killing and they are not
considered statistically meaningful.
Radiation
N + 5 lg l0B/ml BPA







Table 2.12. Interpolated doses and CBE at surviving fraction of 0.2 for the neutron beam
with different concentrations of BOPP using the MTT assay. Shaded results have
uncertainties that are underestimated due to excessive cell killing and they are not
considered statistically meaningful.
Radiation





The CBE values with the same compound at different boron concentrations
(approximately 5, 10, and 20 lag 10B/ml) using the MTT assay are shown in Figure 2.15.
The CBE factors for a given compound were not statistically significantly different with
different boron concentrations for boric acid and BPA. CBE factor should be independent




















Figure 2.15. The CBE values for boric acid (BA), BPA, and BOPP at 5, 10, and 20 tg
'OB/ml using the MTT assay. This graph compares the CBE values of different boron
concentrations for each boron compound.
2-4-7. Evaluation of a test compound
A direct comparison of survival at the same total absorbed dose is another approach
to compare the efficacy of a boron compound at the same boron concentration. Figure 2.16
plots survival curves for SCCVII cells irradiated with the thermal neutron beam in the
presence of boric acid, BPA, and BOPP with approximately equivalent boron
concentrations so as to directly compare the radiation induced effects of the different boron
compounds. Gray arrows point to the survivals (fractional OD) for each boron compound
with the same boron concentration at the same total absorbed dose of 3 Gy which is chosen
as a suitable dose point. At a total absorbed dose, 3 Gy, higher survival was observed from
the test compound, BOPP, than the reference compound, boric acid, which indicates that
the test compound is less effective than boric acid and it does not accumulate preferentially
inside the SCCVII cells. The BPA, serving as a positive control due to the known ability to
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Figure 2.16. Survival curves using the MTT assay for SCCVII cells irradiated with the
neutron beam and with the neutron beam in the presence of boric acid (BA), BPA, and
BOPP. Graphs are represented with approximately the same boron concentration (5 tg
1oB/ml) from three different compounds. Gray arrows indicate survivals (fractional OD) for
each compound at total absorbed dose of 3 Gy.
The efficacy of the test compound, BOPP, was also evaluated by comparing CBE
factors with those of boric acid and BPA at the same boron concentration. As described in
the previous section, CBE factors for higher boron concentration of these boron compounds
were underestimated due to the chemical toxicity or the excessive cell killing. Thus, CBE
values of these compounds with 5 Vg 1oB/ml were analyzed. Figure 2.17 shows a
significantly larger CBE value (6.1 ± 0.7) from BPA than those of boric acid and BOPP.
The comparable CBE values of boric acid and BOPP (3.5 ± 0.5 and 3.3 + 0.7, respectively)
indicate that BOPP has similar biological effectiveness with boric acid and does not
preferentially accumulate in the SCCVII cells.
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Figure 2.17. The CBE values for boric acid (BA), BPA, and BOPP at 5 gg 10B/ml using the
MTT assay.
2-5. Comparison between clonogenic and colorimetric assays
Figures 2.18 and 2.19 compare survival curves (fractional OD) from the colorimetric
(WST-1 and MTT) assay to the survival curves for clonogenic assay for SCCVII cells
irradiated with 250 kVp X-rays and with the thermal neutron beam only, respectively.
Initial optimization experiments were focused on producing good agreement between
WST-1 and clonogenic assays, and so experimental conditions of 100 cells/well (for 2 and
4 Gy of X-rays and 1.7 and 3.3 Gy of neutron beam) or 200 cells/well (for 6 Gy of X-rays
and 5 Gy of neutron beam) with 5 days growth time were used for the WST-1 assay. The
WST-1 and clonogenic assays showed good correlation up to 6 Gy from X-ray irradiation
(Figure 2.18). When the same protocol used for the WST-1 assay was applied to thermal









higher than from the clonogenic assay (Figure 2.19). Since the thermal neutron beam
consists partly of high-LET radiations, overestimated survivals may result from insufficient
cells in each well or a longer cell growth delay caused by high-LET radiation. Experimental
conditions such as cell density and the growth time for each dose point could be optimized
for agreement between the two different assays. In these figures, the protocol for the MTT
assay used a cell density of 500 cells/well with 5 days of growth time, which was not
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Figure 2.18. Survival curves fitted with the linear-quadratic model using the colorimetric
(WST-1 and MTT) and clonogenic assays for SCCVII cells irradiated with 250 kVp X-rays.
Figure 2.19. Survival curves fitted with the linear-quadratic model using the colorimetric
(WST-1 and MTT) and clonogenic assays for SCCVII cells irradiated with the thermal
neutron beam.
2-6. Discussion
The clonogenic assay is generally considered to be the well-accepted standard to test
radiosensitivity of the proliferating tumor cells by directly measuring the reproductive
integrity of individual cells. Despite its worldwide use in basic research, the clonogenic
assay has some disadvantages. It takes a long time, around 2 weeks to allow colonies to
grow to the size needed for counting. There is also no standard in colony counting
procedures, and manual counting of colonies can therefore be subjective and time
consuming. Moreover, this method is difficult to apply to cell lines with very low plating
efficiency. The number of cells initially plated in a Petri dish is critical for obtaining
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are plated, the numbers of colonies are impossible to count due to overlapping colonies. Or,
at very low cell densities, cells cannot form colonies well and counting statistics are poor.
When testing a new compound with an unknown boron effect, the number of cells to
initially plate cannot be practically predicted and experiments must often be repeated to get
the best results. This limiting factor requires more quantity of boron compound to be tested.
When evaluating new compounds which may only be available in small amounts at
the early stages of their development, the quantity of testing boron compound is a critical
factor for developing the evaluation method. In the initial geometry for the clonogenic
assay, when flasks were filled with medium because they were up-side down in the beam,
43 ml of medium was necessary to completely fill a T12.5 flask. If 10 ýtg l0B/ml of boron
concentration is used for testing, 430 pg l'oB is needed in each flask. Eight flasks irradiated
with 4 graded doses will require 3.5 mg loB, and it is frequently not feasible to produce this
much compound for preliminary in vitro tests. With the optimized setup using upright
flasks and 1 ml of medium, only 80 pg l0B is needed for 8 flasks. However, 8 flasks might
not be enough for 4 graded doses. For example, if the survival of cells exposed with a large
radiation dose mainly from boron dose is reduced by three logs (SF = 10-3), at least four
T12.5 flasks are required to plate enough cells in the Petri dishes for counting. Therefore, a
few hundred micrograms of boron would be needed for the clonogenic assay. If the data
from this experiment proves insufficient for any reason (such as low cell plating,
contamination), then further experiment would be required to complete the survival curve
which in turn would require more compounds.
The colorimetric assay uses 96-well plates which need 100 0l of medium per well.
Again using 10 ptg l0B/ml, the colorimetric assay needs only 40 pg l0B when 10 wells are
used for one boron compound in 4 different plates to give 4 graded doses as with the
clonogenic assay. For initial testing a new compound which has an unknown characteristics,
this assay is capable of identifying at least some measurable boron effect from cell
irradiations as well as determining chemical toxicity with this small quantity. Besides using
a very small quantity of boron, the MTT assay has several advantages over the clonogenic
assay. It is a semi-automated method which rapidly and objectively assesses the number of
viable cells using a microplate reader. Since several boron compounds can be tested in one
96-well plate, it saves a lot of time in the entire experiment and especially in the use of
neutron beams. Also, it can be applied to cell lines which have very low plating efficiency.
However, the colorimetric assay has serious limitations. A measurable OD from the
MTT assay is between -0.02 and 3.0, which means that the right amount of cell growth
must be obtained to produce a reasonable OD. Approximately 5 days of growth time is
required for SCCVII cells after an irradiation, but this may be different for other cell lines
with different cell cycle delay and proliferation inhibition [81]. Non-irradiated control cells
have to be still in the measurable OD range at the time of assay and this limits the number
of cells initially plated, which is 500 cells/well for SCCVII cells. This limited number of
cells means that the total absorbed dose (beam + boron dose) is also limited to low levels (<
-3 Gy) as well as the boron concentration to avoid killing too many cells and making the
OD too low. Also, during growth time, cells are exposed to the boron compound and so
chemical toxicity can mask the effects of radiation damage. A long exposure to compounds
with high toxicity like boric acid and a test compound, BOPP, results in very low OD
numbers that are difficult to discern accurately from background OD level, producing very
large uncertainties on the resulting fractional OD.
Since growth delay from radiation damage varies with cell line, the colorimetric
assay requires considerable effort to optimize a standard protocol for each cell line,
especially the number of cells initially plated in each well, growth time, and practical range
of doses including useful boron concentration. Possible improvements to the colorimetric
assay, that would separate curves further (statistically significantly) include changing the
medium after irradiation to avoid toxic effects from the compound and increasing the
growth time to be able to accurately measure OD after higher radiation doses.
Some reports have shown good correlation in direct comparison between MTT
colorimetric and clonogenic assays for determining chemosensitivity [81-83] or
radiosensitivity [69, 80, 84, 85]. After lengthy optimization of the protocol of X-ray
irradiation, WST-1 and clonogenic assay showed comparable survival curves (see Figure
2.18). However, when the same protocol was applied to neutron beam irradiations, the
survival curves showed significant differences between two techniques. Since the purpose
of applying this colorimetric assay is to establish a simple and efficient method for
compound screening, it was decided not to develop this protocol to get good agreement but
instead to observe if the presence of boron was having an effect. The colorimetric assay is
perfectly capable of useful boron compound screening, without such optimization to agree
with clonogenic assay data.
This colorimetric assay was chosen as an initial testing since it could facilitate a
simpler and more efficient method of compound evaluation for determining chemical
toxicity and relative intracellular uptake of compounds using very small quantity which
would be only a few hundred micrograms of l0B. Thus, boronated porphyrin, BOPP was
tested as an example for the usefulness and practicality of the colorimetric assay. In this
chapter, the clonogenic assay could not be used to evaluate BOPP because of insufficient
quantity.
Survival data were fitted to the widely-accepted linear-quadratic model in order to
describe radiation sensitivity of cells with a simple equation [86]. Only two parameters are
used to simulate the basic mechanism of cell killing; a lethal double-stranded break in the
DNA. Most damage from high-LET radiation is lethal and the quadratic component
becomes zero. Thus, a survival curve of high LET-radiation presents simply as an
exponential function. Since a linear-quadratic model is practical to represent survival data
in the first two decades of cell killing, this model described cell survival well, especially the
MTT assay which had most surviving fractions in the first two decades [67]. Also, this
model with only two parameters helped to accurately interpolate dose and reduced the
extent of uncertainty on the calculations of RBE and CBE. As there were only 3-4 survival
points for each irradiation, survival curves fit the linear-quadratic model well.
Cell irradiations in the presence of a reference compound, boric acid, exhibited
decreased cell survival with increasing boron concentration using the clonogenic assay and
this trend also apparent with MTT assay up to 20 ag l0B/ml. Boric acid accumulates in the
cells by diffusion and the boron concentration inside cells therefore increases with
increased boron concentration in the medium. This 1:1 ratio of intracellular/extracellular
boron concentration was proven for GS-9L rat gliosarcoma [71] and was assumed to also
hold for SCCVII cells. At 40 gg l0B/ml, the chemical toxic effects of boric acid became too
large to obtain statistically meaningful results with the MTT assay.
BPA, a positive control compound, showed more cell-killing than boric acid at the
same boron concentration and this indicates that BPA is preferentially accumulated in the
cells. This was shown also in the boron accumulation study for BPA with several tumor
cell lines [71]. With the MTT assay, survival curves using BPA at 5 and 10 [ig l1oB/ml
showed a slight increased effect with increasing boron concentration; however, with 20 and
40 jtg l0B/ml BPA, this tendency was not observed. The extremely high boron dose seems
to kill most of plated cells (which for the MTT assay is fixed at 500 cells/well) and this
resulted in very low OD numbers causing an overestimation of cell survival for high boron
concentration. Therefore, the choice of a useful boron concentration in the medium is
approximately 5-10 gg 1oB/ml for any boron compound to be tested using the MTT assay.
Comparing the survival curve of a test compound with those for boric acid is an
indirect estimation of the intracellular boron accumulation and a test compound, BOPP,
showed non-selective accumulation inside SCCVII cells. In vitro study by others with
BOPP reported that it entered human glioma cells through the low density lipoprotein
pathway [87]. The survival curves using the MTT assay with BOPP were not
distinguishable from each other especially considering the error bars and this agrees with
literature report that similar amounts of BOPP may be present in the cells during
irradiations regardless of the BOPP concentration in the medium [87]. Also, the survival
with BOPP was similar to that of boric acid at the same concentration especially
considering the estimated uncertainties as was reported in studies using V79 Chinese
hamster ovary cells [61]. Cytotoxicity experiments for rat C6 glioma cells proved that
BOPP was toxic [88], which agrees with our toxicity observation for SCCVII cells.
The mixture of different-LET radiations during BNCT has different effectiveness in
biological systems. In order to quantitatively compare the efficacy of different types of
radiation, the neutron beam RBE relative to 250 kVp X-rays was determined. Thus, the
RBE of 250 kVp X-rays is defined as 1. The RBE of the neutron beam including the high-
LET components for SCCVII cells was 1.1 + 0.1 at surviving fraction of 0.02 using the
clonogenic assay and 1.2 + 0.1 at surviving fraction of 0.2 using the MTT assay. A higher
surviving fraction of 0.2 was chosen for the colorimetric assay since the dynamic range of
this assay was limited. This value agreed with the beam RBE (1.2 + 0.1) from previous
small animal experiments with rat lung irradiation at the thermal neutron beam of the
MITR-II [89]. The RBE varies mostly from quality of radiation, types of biological system,
and the chosen biological endpoint. Thus, the RBE values are different for neutron beams
that have different beam characteristics. The RBE of the BMRR beam for example was 2.6
for 9L gliosarcoma cells, and this high RBE mainly resulted from a high percentage (43 %)
of fast neutron dose component in the neutron beam [62].
The CBE factor was introduced to quantitatively compare the biological efficacy of
different boron compounds. The CBE, also, depends on characteristics of the boron
compound, types of biological system, and a given biological endpoint. Especially,
microscopic distribution of boron in the cell primarily affects CBE factor due to the short
ranges of particles produced by the boron neutron capture reaction. As there is no
straightforward and reliable method to measure intracellular boron concentration at the time
of irradiation in vitro, the boron dose component is calculated using the boron
concentration measured in the growth medium. A CBE value of a test compound larger
than that of boric acid can be interpreted as preferential intracellular accumulation relative
to the boron concentration in the medium.
The CBE values of a particular boron compound did not vary statistically
significantly for different boron concentrations using both clonogenic and colorimetric
assays. Thus, the average CBE value of boric acid from different boron concentrations is
2.8 ± 0.2 at a surviving fraction of 0.02 for the clonogenic assay (5-10 pag loB/ml) and 3.9 ±
0.3 at a surviving fraction of 0.2 for SCCVII cells using the MTT assay (5-20 pg l'oB/ml).
BPA showed a significantly higher average CBE, 5.7 ± 0.4, at a surviving fraction of 0.2
using the MTT assay (5-10 pg 1oB/ml), which verifies that BPA can more accumulate
inside SCCVII cells. This larger CBE value of BPA than that of boric acid was also
reported in the study of 9L gliosarcoma cell irradiation with the neutron beam of the
BMRR (RBE = 2.6) [62]. The CBE values was 3.4 for boric acid (at a surviving fraction of
0.1 and 0.01) and 9.8 (at surviving fractions of 0.1) for BPA using the clonogenic assay
[62].
The uncertainty analysis for CBE value has not been comprehensively investigated
during in vitro and in vivo studies for BNCT. In this chapter, the uncertainty analysis was
started with calculating the fitting uncertainty of interpolated dose using the standard errors
of the fitting coefficients (a and f3). These fitting uncertainties were averaged for each assay
(2.8 % for the clonogenic assay and 3.5 % for the MTT assay) and combined with the
dosimetry measurement uncertainty (3 % for X-rays, 5 % for neutron beam, and 7 % for
boron). Total uncertainties on the interpolated dose at the endpoint were estimated to be
4 % and 4.6 % for X-rays, 5.7 % and 6.1 % for the neutron beam, 7.5 % and 7.8 % for
boron using the clonogenic and MTT assays, respectively. The uncertainty of beam RBE
was approximately 7 % for the clonogenic and MTT assays. The estimated uncertainties of
CBE for the 5 and 10 tg loB/ml were -12 % for boric acid, -11 % for BPA, and -18 % for
BOPP. Relatively large uncertainties of CBE cause difficulty in precisely comparing the
efficacy of a test compound to those of boric acid and BPA. This large uncertainty also
indicates that investigators should be very careful when a general CBE factor is applied to
another study for the same endpoint using a different biological system (e.g. humans). This
large uncertainty must be recognized as a major source of experimental error especially for
a study in which the dose-response relationship is steep and a slightly different dose would
cause a large change in outcome.
An alternative approach to compare the efficacy of each boron compound can be
considered due to the large uncertainty of CBE obtained by comparing with X-ray
irradiation. Since boric acid is used as a reference boron compound, the efficacy of a test
compound can be directly compared with that of boric acid at the same boron concentration.
For this, a new parameter (C) which is defined as 1 for boric acid can be introduced in the
following equation.
(DoseBeam )BA x (RBE) + (DoseBoron )BA x (1)
= (DoseBeam )testing compound x (RBE) + (DoseBoron )testing compound x (C)
Using this relation, if a test compound produces this new parameter (C) larger than 1 like
BPA (2.2 + 0.2), this test compound is more effective than boric acid. The new parameter
of the test compound, BOPP is less than one, indicating that BOPP is not as effective as
boric acid. This "effectiveness" can be also interpreted as relative intracellular
accumulation compared with the boron concentration in the medium.
In conclusion, the optimized in vitro compound screening includes:
1) identifying the chemical toxicity of a new compound using the MTT assay,
2) determining boron effects from cell irradiation in the presence of a test compound
compared with boric acid and BPA at the same boron concentration of 5-10 jtgloB/ml using
the MTT assay,
3) optimizing experimental conditions (especially, the number of cells initially plated in the
Petri dish) for the clonogenic assay,
4) verifying promising boron compound for further in vivo study using the clonogenic assay.
2-7. Summary
In vitro compound screening was established in the laboratory for determining initial
suitability of boron compounds by assessing preferential intracellular uptake. Boric acid is
used as the reference for identifying intracellular uptake since it uniformly distributes in the
intra- and extra-cellular compartments. If cell irradiation in the presence of a test compound
produces more cell killing than in the presence of boric acid at the same concentration in
the growth medium, then the test compound is considered to be preferentially accumulating
in tumor cells. In this work, cell irradiation with BPA produced significantly more cell
killing than with boric acid, consistent with earlier in vitro studies using 9L gliosarcoma
cells [62]. The test compound, BOPP, produced similar cell killing with the reference boric
acid, as was reported in studies using V79 Chinese hamster ovary cells [61]. The BOPP
chemical toxicity data from the colorimetric assay is also consistent with published report
[88].
Using the colorimetric assay requires only limited quantities of compound
(approximately a hundred micrograms of 10B) and can determine data relevant to chemical
toxicity and intracellular uptake which otherwise would not be obtainable from the
clonogenic assay. This preliminary information is useful for optimizing subsequent studies
using the clonogenic assay. The survival data obtained from the colorimetric assay is used
to estimate the number of cells required for plating in the clonogenic assay and minimizes
the amount of compound necessary to obtain a full survival curve from which the relevant
radiobiological data can be determined.
CHAPTER THREE
IN VIVO EVALUATION OF BORONATED LIPOSOMES
3-1. Introduction
In vivo evaluation in a small animal model of a new boron compound is the critical
procedure to establish the potential radiobiological effectiveness of a new compound for
BNCT. Low molecular weight compounds which have shown promising results during in
vitro screening process can be candidates for such further study. In addition, in vivo
evaluation may be the first testing performed on some high molecular weight compounds
for which in vitro testing is not particularly suitable. Moreover, some compounds may be
designed for specific metabolic modification as part of their targeting mechanism and
would require testing in specific tumor models. For example, a nucleoside that needs
phosphorylation by thymidine kinase (TK) [49] to remain inside cells could be tested in
TK+ and TK- tumors to demonstrate that the metabolic targeting is actually working.
In vivo testing requires neutron irradiation when the 'oB distribution is optimal (i.e.
high concentration and good selectivity in tumor) for tumor therapy. Thus, the first step of
in vivo testing is a biodistribution study to ensure enough boron is delivered to tumor by the
test compound and to measure uptake in other tissues, such as blood, skin, and other
important organs, as a function of time after injection. This data is essential for later studies
testing efficacy as the best time post administration for an irradiation has to be determined.
A boron compound that delivers sufficient 1oB to tumor warrants a tumor therapeutic
response study to evaluate the therapeutic effectiveness of this compound at the time
chosen for BNCT based on the biodistribution study. The microscopic distribution of o0B
within the tumor greatly affects the uniformity of radiation dose absorbed within the tumor,
and thus the effectiveness of the therapy. A microscopic analysis of the l0B biodistribution
within the tumor should be performed if possible as this can provide information to help
explain the observed radiation effects.
Liposomes are small unilamellar vesicles with a membrane of phospholipid bilayer
that are widely studied for drug delivery. They have very low toxicity due to the similarity
to biomembranes and liposomes are therefore generally safe for use in the humans without
serious side effects [90]. They can deliver drugs either through diffusion or through
endocytic action. The attractive property of liposomes as a boron delivery vehicle for
BNCT is their ability to accumulate in tumors. This feature results from the increased
permeability through leaky tumor vessels and slower clearance from tumors than normal
tissues [91]. Thus, an active tumor-targeting property is thought not to be required for the
incorporated boron species within the liposomes. In addition, this specificity of liposomes
allows the delivery of greater quantities of boron at lower administered doses [92].
Professor M. Frederick Hawthorne's research group at the University of Missouri,
Columbia, has spent many years developing liposomes that incorporate loB-containing
molecules as boron delivery agents. Some of these boronated liposomes showed promising
in vivo uptake in EMT-6 murine mammary tumors [92-95]. Metastatic brain tumors or
recurrent disease from primary breast cancer have been suggested as possible candidates for
BNCT. Liposomes may be especially attractive for metastatic brain tumors because the
blood-brain barrier keeps liposomes out of normal brain but is often comprised in tumors.
Also, recurrent tumors which usually spread all over the chest wall are difficult to treat with
surgery or conventional radiation therapy because of radiation damage to normal tissues
from the initial treatment. Thus, the selective targeting ability of BNCT can be an
advantage in the treatment of this tumor.
In this chapter, an in vivo evaluation study of boronated liposomes supplied by
Professor Hawthorne's research group is performed for BNCT in a murine mammary
carcinoma, EMT-6 tumor model. A current best compound in BNCT, BPA, was used as a
positive control to compare the effectiveness of BNCT.
3-2. Materials and methods
3-2-1. Tumor model
The EMT-6 murine mammary carcinoma was used as a tumor model of breast cancer.
The EMT-6 tumor was chosen for evaluating the effectiveness of liposomes to build upon
promising preliminary biodistribution studies of boronated liposomes in this model have
already reported to show selective tumor uptake and long-retention of boron in tumor
relative to normal tissues [92-95].
The EMT-6 cell line (kindly provided by Brookhaven National Laboratory) was
grown in Dulbecco's Modification of Eagle's Medium (DMEM, Mediatech) supplemented
with 10% fetal bovine serum (SeraCare Life Science), 1 % 200 mM L-glutamine
(Mediatech), and 1 % 5,000 I.U./ml penicillin - 5,000 tg/ml streptomycin (Mediatech) at
37 oC in an atmosphere of 5 % CO2. Cells were used for transplantation when the
monolayer reached -90 % confluence. Each female BALB/c mouse was anesthetized with
isoflurane, and then 106 EMT-6 cells in a volume of 0.1 ml were injected subcutaneously
on the lower back.
3-2-2. Liposomes
Liposomes are small unilamellar vesicles which consist of a phospholipid bilayer
composed of distearoylphosphatidyl choline (DSPC) and cholesterol and an interior
aqueous core [92]. The liposomes produced by the Hawthorne group for this project
generally had diameters of 60-100 nm and contained 24 mg total lipid/ml (Figure 3.1).
There are two ways for incorporating boron species (Figure 3.2): (1) MAC-16, lipophilic
boron compounds, [nido-7-CH 3(CH 2)1 5-7,8-C 2B9H1 i]-, are embedded within the
phospholipid bilayer, or (2) TAC, hydrophilic, a water-soluble boron compound,
[B20H 17NH3]3- , is trapped within the aqueous core of the liposome. In addition, both types
of boron compounds can be combined within the same liposomal formulation, which is
called MAC+TAC.
In our experiments, we used MAC-16 and MAC+TAC, which were prepared in
hypertonic solution. Liposome solutions were provided in batches of -7-10 ml. Each batch
had a different liposome size and boron concentration. Liposome mean diameter varied
from 59-70 nm. Solution concentrations varied from 475 to 580 in tg l0B/ml for MAC-16
solutions and from 1215 to 2195 in tg l0B/ml for MAC+TAC solutions. From these
solutions, injected doses for therapy studies were maximized with concentrations of 580
and 2195 gg '0B/ml for MAC-16 and MAC+TAC solutions, respectively. The injected
doses are indicated in each table and graph. Thus, different batches of liposome solutions
were used for biodistribution studies. When data were compared from different








Figure 3.1. A cross-sectional view of a small unilamellar vesicle and the structure of








Figure 3.2. Structures of (1) MAC-16, the lipophilic boron species, [nido-7-CH 3(CH 2)1 5-
7,8-C2B9H1 1], which is embedded in the bilayer and (2) TAC, the hydrophilic ion,
[B20H17NH3] 3- , which is encapsulated in the aqueous core.
3-2-3. Biodistribution study
Murine biodistribution studies used female BALB/c mice (17-22 g), with EMT-6
tumors implanted subcutaneously on the lower back at 8 days before the experiments. Each
mouse received an i.v. injection of 0.2 ml liposome solution into the retro-orbital sinus
while under brief isoflurane anesthesia. Retro-orbital injections do not damage the eye or
affect the vision. Also, retro-orbital injections showed comparable uptake results to tail vein
injections. Five to seven tumor-bearing mice were used at each time point of sacrifice and
were euthanized by isoflurane overdose. Blood was removed directly from the heart, and
tumor and liver were collected for boron analysis. Tumor volume at the time of sacrifice
ranged from 50 to 200 mm3.
A biodistribution study of MAC-16 was carried out first at sacrifice times of 6, 24, 30,
and 48 hours after injection. An initial MAC+TAC biodistribution study was performed at
30 hours after injection, which was determined by considering our MAC-16 biodistribution
study and the published liposome biodistribution studies. Subsequently, a complete
MAC+TAC biodistribution study was carried out for the sacrifice times of 6, 18, 24, 30,
and 48 hours which were chosen based on previous studies [92-94].
A BPA biodistribution study was included for comparison. BPA (0.2 ml, 4.3
mgloB/ml) was injected intraperitoneally (i.p.) as the BPA-fructose complex (BPA-F) to
improve the solubility. Tumor and blood were collected at 2, 4, and 6 hours after
administration.
Macroscopic 10B quantification of blood and tissues was carried out using PGNAA in
the MITR-II. PGNAA is a non-destructive analytical technique and does not restrict the
shape, size, or chemical form of samples. PGNAA detects the 478 keV photons produced
from boron neutron capture reactions in 1oB: the detection limit is 1 [ig 10B [76].
3-2-4. Tumor therapeutic response study
Tumor therapeutic responses were evaluated using female BALB/c mice (17-22g)
bearing EMT-6 tumors implanted subcutaneously on the back 8 days prior to the
experiments. Experiments involved irradiation of tumors with graded doses of thermal
neutrons in the presence of liposomes (MAC-16 and MAC+TAC), thermal neutrons in the
presence of BPA, thermal neutrons alone, or 250 kVp X-rays. Additional controls included
mice whose tumors received no irradiation. Five to eleven mice were used for each
irradiation group.
Animal irradiations were performed using the vertical M011 thermal neutron beam in
the MITR-II and using a shielding box made of lithiated-polyethylene (Li-Poly; 93 % 6Li-
enriched Li 2CO 3 dispersed in polyethylene; 7.5 % total Li by weight; Reactor Experiments,
Sunnyvale, CA [89]). The lid of the box has a 10 cm x 2 cm irradiation aperture providing a
narrow irradiation field across the backs of the mice. Four mice, which were anesthesized
with ketamine-xylazine, were positioned side-by-side under the lid of the box (Figure 3.3).
Then, the shielding box was mounted in the thermal neutron beam line shutter that turns the
beam on and positions the shielding box aperture in the center of the neutron field. The
absorbed dose rates on the tumor site with thermal neutron beam were presented in Table
3.1.
Table 3.1. The absorbed dose rates on the tumor site with the thermal neutron beam at the
MITR-II.
Absorbed dose rate (cGy/min)
BoronNitrogen Fast neutron Photons ( rg
(per <Lg 1B/g)
13.0 + 0.6 < 0.1 19.8 ± 1.0 4.0 + 0.2
Figure 3.3. Positioning 4 anesthesized mice under the lid of the shielding box that provides
narrow irradiation field across the backs of the mice during irradiation in the thermal
neutron beam at the MITR-II.
Neutron irradiations with liposome-mediated BNCT were carried out at 30 hours
after retro-orbital injection of 0.2 ml of the liposome solution with neutron beam doses of 4,
6, and 8 Gy. This dose range was selected knowing that 10 Gy neutron beam is not well
tolerated by the animals and we want to give graded doses up to that maximum so as to be
able to establish a dose response. The quantity of boron in each injected dose was
maximized based on the concentration of a stock solution supply (5.8 tg l'oB/gbw (gram of
body weight) for MAC-16, 22.0 tg 0 B/gbw for MAC+TAC). BPA-mediated BNCT used
irradiations 4 hours after i.p. injection of 0.2 ml BPA-F and neutron beam doses of 6 and 8
Gy. Injected dose of BPA-F (43 gg l'oB/gbw) was maximized based on the solubility of
BPA.
In addition, to see whether there was any therapeutic effectiveness when liposomes
target tumor vasculature, the irradiations were tried at 30 minutes after liposome injection
while the blood boron concentration was still high. At the time of irradiation, blood boron
concentration was -40 jtg loB/g from MAC-16 and -100 gg 'oB/g from MAC+TAC. In this
case, a neutron beam dose of 8 Gy was used to see the maximum effect.
A Phillips RT250 unit in the MIT Nuclear Science and Engineering Department was
used for X-ray irradiations operating at 250 kVp and 15 mA utilizing filtration of 0.4 mm
Sn plus 0.25 mm Cu. The same shielding box for the thermal neutron irradiations was used
with the top of the box replaced by 5 mm-thick lead having the same 10 cm x 2 cm
irradiation aperture. The irradiation box was positioned on a platform with a focus-to-target
distance of 10 cm which gave a dose rate of 2 Gy/min. Total X-ray doses of 20 and 30 Gy
were administered.
To evaluate the tumor response, tumor volume was measured daily for 2 weeks after
irradiations. After the initial 2-week period, tumor volume was measured 2-3 times per
week until only mice whose tumors were controlled remained. Tumor volume was
calculated from orthogonal length and width measurements using the formula for an
ellipsoid V = (ab2)/2, where a is the larger of the two diameters. Mice were sacrificed if the
tumor became necrotic or its volume exceeded 500 mm3. If the tumor was controlled, mice
were kept and observed for 6 months to check for tumor recurrence.
3-2-5. Microdistribution study
To observe microscopic distribution of boron, MAC-16 liposome incorporated with
fluorescent rhodamine phospholipids incorporated into the bilayer were first tried. At 30
hours after retro-orbital injection of fluorescent liposomes, tumor was harvested and
immediately frozen in Tissue-Tek with dry ice, and then it was stored in the -80 oC freezer.
Sections of tissue sample were cut at -4 pm using a cryotome (Thermo Electron
Corporation), and then mounted on a microscope slides. This would be useful for
determining liposome distribution in tumor. Although the fluorescent marker was not
directly attached to the boron species, it showed co-localized position of boron and
liposomes.
High resolution quantitative autoradiography (HRQAR) is a powerful tool that can
visualize tracks from boron-neutron capture reactions superimposed on tissue histology
from thin (2-4 pim) frozen tissue sections [96]. This technique has been developed in
Professor Otto K. Harling's laboratory in the MIT Nuclear Reactor Laboratory and the
Department of Nuclear Science and Engineering [97, 98].
HRQAR analysis within the tumor was performed at one time point; the optimum
time as indicated by the biodistribution studies (30 hours after retro-orbital injection of
liposome solution and 4 hours after BPA-F i.p. injection). Thin tissue sections were
mounted on microscope slides coated with 2 polymers and then irradiated with thermal
neutrons. Since one of two polymers was a thin layer of nuclear track detector, a particle
tracks from boron neutron capture reactions were recorded. After several procedures
including tissue staining and track etching, the boron microscopic distribution was visible
as black dots of etched tracks together with the stained tissue histology that are viewed
under a light microscope. HRQAR images were produced by Thomas Harris and Dr. Kent
Riley, and detailed methods are described in the reference [96, 97].
3-3. Results
3-3-1. Biodistribution study
3-3-1-1. MAC-16 biodistribution study
Table 3.2 and Figure 3.4 show boron concentrations in tumor, blood, and liver as a
function of time after MAC-16 administration. All tumors in each time group were added
together and measured together to increase the loB signal in PGNAA. Thus, the loB
concentrations in tumor have a 5 % error in measurement from PGNAA. However, blood
and liver were each measured separately and error bars represent standard deviation (SD) of
7 mice. While boron concentrations in blood and liver decreased slowly over the time
period, boron continued to accumulate in the tumor. The maximum boron concentration in
tumor of 18.4 + 0.9 gg 1oB/g, was reached at 30 hours after injection with the tumor to
blood (T/B) boron concentration ratio of 0.90. The average blood and liver values at 30
hours were 20.5 + 4.2 jig 'lB/g and 12.0 + 2.9 jtg 1oB/g, respectively.
Table 3.2. 0oB concentrations at different times after MAC-16 retro-orbital injection with an
injected dose of 4.8 gg 1oB/gbw (gram of body weight). Results are expressed as the mean
+ SD for 7 mice except tumor. The tumor errors represent a 5 % error in measurement from
the PGNAA.
Time after MAC-16 10B concentration (jig loB/g)
administration (hrs) Tumor Blood Liver
6 11.6 + 0.6 42.9 + 3.7 20.1 + 1.9
24 16.8 + 0.8 22.9 ± 4.6 12.6 + 2.7
30 18.4 ± 0.9 20.5 ± 4.2 12.0 + 2.9
48 15.9 + 0.8 10.6 ± 1.6 6.2 + 1.5
Figure 3.4. 10B concentrations (jtg l0B/g) versus time (hours) post-injection for MAC-16
with retro-orbital injection dose of 4.8 tg loB/gbw. Points represent the mean + SD for 7
mice except tumor which is a single measurement on several pooled tumors. The tumor
error bars represent a 5 % error in measurement from the PGNAA. Lines are drawn
connecting the data to help guide the eye.
These experiments were repeated to confirm the uptake data for the most promising
time point (i.e. 30 hours). Table 3.3 shows boron concentrations in blood and tissues at 30
hours after MAC-16 administration. Injection dose was increased 18 % due to the use of a
different batch of MAC-16 solution. However, loB concentration in the tumor was
comparable to the previous study. The large SD (34 %) on the loB concentrations in tumor
may mask any effects of the increased injected dose. 'oB concentrations in blood and liver
were different from previous study, which could be due to the different liposome size in
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Table 3.3. 1oB concentrations at 30 hours after retro-orbital injection of MAC-16 with an
injected dose of 5.8 lig loB/gbw. Results are expressed as the mean ± SD for 5 mice.
Time after MAC-16 o1 B concentration (jlg loB/g)
administration (hrs) Tumor Blood Liver
30 18.3 + 6.3 13.9 ± 2.1 21.0 + 4.0
3-3-1-2. MAC+TAC biodistribution study
Table 3.4 presents boron concentrations of tissues at 30 hours after MAC+TAC
administration. The biodistribution study of MAC+TAC shows an average loB
concentration in tumor of 32.2 jg 1OB/g at 30 hours after injection with a T/B ratio of 0.63.
This l0B concentration in tumor meets one of the requirements for new boron compounds to
deliver sufficient l0B to tumor to allow therapeutic doses of radiation to the tumor during
BNCT. Although MAC+TAC produced a relatively high loB concentration in liver, 75.7 jig
loB/g, this can be tolerated because the liver will be located under the shielded from
neutrons during the irradiation.
Table 3.4. l0B concentration in tissues at 30 hours after MAC+TAC retro-orbital injection
of 15 jg l'oB/gbw. Results are expressed as the mean ± SD with 5 mice for tumor and liver
and with 3 mice for blood.
Time after MAC-16 l0B concentration (jig loB/g)
administration (hrs) Tumor Blood Liver
30 32.3 ± 11.0 51.2 + 2.5 75.7 + 5.3
As was done for MAC-16, an additional MAC+TAC biodistribution study at the 30
hour-time-point was performed to confirm the consistency of experiments. Table 3.5
presents loB concentrations in blood and tissues at 30 hours after MAC+TAC
administration for the repeated experiment. Due to the higher injected dose, the average loB
concentration in tumor, 42.9 gg loB/g, seems higher than previous results, 32.3 jtg l'oB/g;
however, the large SD (-30 %) on the 10B concentrations in tumor masks the effect of the
increased injected dose.
Table 3.5. 10B concentrations at 30 hours after retro-orbital injection of MAC+TAC with an
injected dose of 22.0 pg loB/gbw. Results are expressed as the mean + SD for 5 mice.
Time after MAC-16 1oB concentration (lg 1oB/g)
administration (hrs) Tumor Blood Liver
30 42.9 ± 11.9 58.1 + 10.9 71.4 + 11.4
A complete biodistribution with MAC+TAC solution was carried out from 6 to 48
hours after retro-orbtial injection using an injected dose of 12.2 pg loB/gbw (Table 3.6 and
Figure 3.5). The maximum l°B concentration in tumor reached approximately 24 pg loB/g
between 18 and 30 hours after liposome injection. This result agreed with previous
experiments after normalizing data to the same injected dose. Boron in blood was cleared
out during the observation time and washout was also evident in liver with a slower rate.
All skin samples (which were not presented in Table 3.6 and Figure 3.5) showed very low
10B concentrations, most at or below the detection limit of -1 jig loB/g and none greater
than 4 pg loB/g.
Table 3.6. 10B concentrations after retro-orbital injection of MAC+TAC with an injected
dose of 12.2 pg loB/gbw. Results are expressed as the mean ± SD for 3-5 mice.
Time after MAC+TAC 10B concentration (pg 1oB/g)
administration (hrs) Tumor Blood Liver
6 16.1 + 2.5 79.2 + 8.2 63.8 ± 7.1
18 26.0 ± 4.2 53.3 0.8 44.6 ± 4.9
24 23.2 ± 2.9 37.7 ± 3.0 55.4 ± 4.6
30 25.2 ± 7.2 28.7 ± 3.7 55.6 ± 3.2
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Figure 3.5. IoB concentrations (tg loB/g) versus time (hours) after retro-orbital injection of
MAC+TAC with an injected dose of 12.2 gtg loB/gbw. Points represent the mean + SD for
3-5 mice. Lines are drawn connecting the data to help guide the eye.
An additional experiment from 30 to 96 hours confirmed that 10B uptake in the tumor
decreased after the 30-hour time point. Figure 3.6 shows boron concentrations of this
additional experiment combined with the previous data (Figure 3.5) normalized to the same
injected doses. Boron in the blood and liver is continuously cleared out and also boron in
tumor starts washout after 30 hours.
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Figure 3.6. '0B concentrations (jtg 1oB/g) versus time (hours) of MAC+TAC. Solid symbols
present data with i.d.= 17.8 tg loB/gbw and open & cross symbols show data from the
earlier experiment (i.d.= 12.2 gg loB/gbw) normalized to the same injected dose using a
factor of 1.47. Solid lines show the trend of boron concentrations.
3-3-1-3. BPA biodistribution study
Figure and Table 3.7 show the l0B concentrations in tumor and blood as a function of
time. Unlike liposomes, BPA is a small molecule and shows fast blood clearance and tumor
uptake. The average loB concentration in tumor at 4 hours after BPA-F i.p. injection was
21.6 gg loB/g with a T/B ratio of 2.3. Average loB concentrations in tumor from MAC-16
at 30 hours after administration were comparable (20 jg 1oB/g) with those from BPA (at 4
hours) and a tumor therapeutic response study and a microdistribution study were therefore
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Figure 3.7. 'oB concentrations (pg loB/g) versus time (hours) after BPA-F injection (0.2 ml,i.p. 43.0 lg l'oB/gbw). Points represent the mean ± SD for 5 mice. Lines are drawn
connecting the data to help guide the eye.
Table 3.7. 10B concentrations at different times after BPA-F i.p. injection of 43.0 jig
loB/gbw. Results are expressed as the mean ± SD for 5 mice.
Time after BPA-F l0B concentration (lg l'oB/g)
administration (hrs) Tumor Blood
2 24.8 ± 3.0 14.7 ± 1.6
4 21.6 ± 5.9 9.6 ± 1.8
6 10.5 ± 2.6 6.0 + 1.1
3-3-2. Tumor therapeutic response study
Table 3.8 summarizes the fraction of tumors controlled for the different treatment
groups. BPA-mediated treatment showed a superior result attaining 62.5 % tumor control.
MAC-16, delivered 30 hours before irradiation with 6 Gy of thermal neutron beam was the
best for liposomes, with 27.3 % tumor control. Although MAC+TAC showed almost twice
the loB concentration in tumor relative to MAC-16, and a higher neutron beam dose (8 Gy)
was used with the MAC+TAC liposomes, no improvement in tumor control was observed.
An additional experiment using the same conditions was performed to confirm these results.
However, this repeat experiment did not control any tumors. A single pilot study using
liposomes administered 30 minutes before irradiation to produce vascular damage into
tumor did not control any tumors.
Figures 3.8 to 3.12 present measured tumor volumes of each mouse after irradiation
for the 6 Gy neutron beam alone and 6 Gy neutron beam in the presence of MAC-16,
MAC+TAC, or BPA, respectively. All groups have evident growth delay post-irradiation
with varying recovery rates. In the 6 Gy neutron beam alone group, growth suppression was
initially maintained for -6-7 days post-irradiation, but the tumors were quick to recover.
The 6 Gy neutron beam in the presence of MAC-16 groups for both the first and the
repeated experiments show a longer growth delay period of -11-13 days post-irradiation.
Growth suppression periods of -14-16 days or -16-18 days post-irradiation were observed
in the 6 Gy neutron beam in the presence of MAC+TAC or BPA, respectively. Some
animals were sacrificed with tumors at smaller than 500 mm 3 due to apparent necrosis of
the tumor.





20 Gy X-rays 1/5
30 Gy X-rays 4/5
4 Gy thermal neutron beam 0/8
6 Gy thermal neutron beam 0/8 (Figure 3.8)
8 Gy thermal neutron beam 0/8
MAC-16 (30 hr) - 4 Gy beam (+ 9.8 Gy boron) 0/11
MAC-16 (30 hr) - 6 Gy beam (+ 14.6 Gy boron) 3/11 (Figure 3.9)
MAC-16 (30 hr) -6 Gy beam (+ 14.6 Gy boron) (Repeat) 0/8 (Figure 3.10)
MAC-16 (30 hr) - 8 Gy beam (+ 19.5 Gy boron) 1/8
MAC+TAC (30 hr)- 4 Gy beam (+ 19.5 Gy boron) 0/8
MAC+TAC (30 hr) -6 Gy beam (+ 29.3 Gy boron) 1/8 (Figure 3.11)
MAC+TAC (30 hr) - 8 Gy beam (+ 39.0 Gy boron) 2/8
MAC-16 (30 min) - 8 Gy beam (+ 39.0 Gy boron - blood) 0/8
MAC+TAC (30 min) - 8 Gy beam (+ 97.6 Gy boron - blood) 0/6
BPA (4 hr) -6 Gy beam (+ 14.6 Gy boron) 5/8 (Figure 3.12)
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Figure 3.8. Tumor volume (mm3) versus time (days) after 6 Gy neutron beam irradiation.
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Figure 3.9. Tumor volume (mm3) versus time (days) after 6 Gy neutron beam irradiation in
the presence of MAC-16. Each line indicates tumor volume for each mouse.
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Figure 3.10. Tumor volume (mm 3) versus time (days) after 6 Gy neutron beam irradiation
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Figure 3.11. Tumor volume (mm3) versus time (days) after 6 Gy neutron beam irradiation
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Figure 3.12. Tumor volume (mm 3) versus time (days) after 6 Gy neutron beam irradiation
in the presence of BPA. Each line indicates tumor volume for each mouse.
3-3-3. Microdistribution study
Figure 3.13 (A) is an unstained frozen section of EMT-6 tumor from a BALB/c
mouse which received a retro-orbital injection of fluorescent liposomes 30 hours before
sacrifice. Fluorescence microscopy showed that the liposomes (brown) were located almost
exclusively at the edges of the tumor. This non-uniformity was independently confirmed
using HRQAR images with liposomes. Figure 3.13 (C) and (D) are HRQAR images of the
EMT-6 tumor after MAC-16 injection via the retro-orbital sinus, which was the same
condition with the therapy. Boron neutron capture reactions appear as small black dots on
the image, called tracks. Tracks are evident only near the periphery of the tumor. However,
in Figure 3.13 (B), when delivered by BPA using the same condition with the therapy,
tracks are uniformly distributed throughout the tumor interior. Although BPA and MAC-16
have similar bulk '0B concentrations in the tumor, they showed very different uptake



















Figure 3.13. Microdistribution images of the EMT-6 tumor. A) Liposomes labeled with a
fluorescent marker (brown) that are concentrated at the edge of the tumor. Scale bar: 100
tm. B) HRQAR image of the tumor that received a BPA injection to visualize boron-
neutron capture particle tracks (black dots) superimposed on the histology, that are
uniformly distributed throughout the tumor interior. Scale bar: 10 pm C-D) HRQAR
images of the tumor received MAC-16 injection superimposed on the histology, where
tracks are evident only near the periphery of the tumor. Scale bar: 10 pm. (HRQAR images
produced by Thomas Harris.)
Figure 3.14. HRQAR image of the EMT-6 tumor that received a MAC+TAC injection to visualize boron-neutron capture particle
tracks (black dots) superimposed on the histology. Track clusters are evident near the periphery of the tumor in the upper right
and left of the low magnification image. The track density (boron concentration) also appears to decrease near the center of the
tumor, as shown in the inset. Arrows indicate the edges of the tumor. Scale bar: 200 [im for the left and 50 pm for the right.
(HRQAR image produced by Dr. Kent Riley.)
Figure 3.14 showed HRQAR section of an EMT-6 tumor harvested from a mouse 30
hours after injecting 0.2 ml MAC+TAC via the tail vein. Gross boron concentrations do not
vary with two different i.v. injections via the tail vein and via retro-orbital sinus. Track
clusters are evident near the periphery of the tumor in the upper right and left of the low
magnification image. The track density (boron concentration) also appears to decrease near
the center of the tumor, as shown in the inset.
3-4. Discussion
The critical qualifications of a compound for BNCT are generally a sufficient
macroscopic loB uptake (20-30 gg 10B/g) in the tumor and a high T/B and T/NT (tumor to
normal tissues) 1oB concentration ratio. In this in vivo liposome study, the gross IoB
concentrations in the EMT-6 tumor from MAC-16 and BPA were comparable and
produced a total absorbed dose (21 Gy: 6 Gy beam + 15 Gy boron) in the tumor that is
sufficient to cause a response to tumor. MAC+TAC produced twice the loB tumor
concentration of MAC-16 and BPA. However, the therapy experiments using liposomes
(MAC-16 or MAC+TAC) were less effective than those with BPA or X-rays. The major
reason appears to be an inhomogeneous microscopic distribution of '0lB delivered by
liposomes in the EMT-6 tumor. These results indicate the importance of a homogenous
microdistribution of 10B in the study of new boron compounds for BNCT.
Liposomes with a size of 50-200 nm accumulate passively in the tumor by passing
through the leaky vasculature of the tumor when they are injected intravenously (i.v.) [99,
100]. Since MAC-16 and MAC+TAC liposomes had an average diameter of 59-70 nm,
these liposomes could be expected to passively pass from the tumor vasculature into the
interstitial fluid within, the EMT-6 tumor. However, fluorescent-labeled liposomes and
HRQAR images showed boron accumulating mostly at the edge of the tumor. This
condition may be caused by the configuration of the EMT-6 tumor. The EMT-6 tumor is a
poorly-vascularized solid tumor. As seen in Figure 3.15, there are some hypoxic areas and
necrotic regions located in the center of tumor. Due to this nature of the EMT-6 tumor,
liposomes can accumulate mostly in areas which are relatively well-vascularized.
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Figure 3.15. Histological section of a paraffin embedded EMT-6 tumor. Brown area
indicates hypoxic (H) region with immunostaining for pimonidazole binding. To the left
side of the brown region is well oxygenated (0) EMT-6 tumor, and to the right of the
brown region is necrosis (N). Nuclei were stained blue. Scale bar: 100 pmn. (Histology
image produced by Jugal Shah.)
In general, higher T/B and T/NT l0B concentration ratios suggest safer therapy with a
minimized background radiation dose to surrounding normal tissue. However, in spite of
lower T/B '0B concentration ratios (0.6-0.9) with liposomes, there was no serious normal
tissue complication observed because the mice were well shielded during irradiations. Thus,
mice in the liposome-mediated BNCT group were all sacrificed due to tumor overgrowth or
necrosis. Mice in the group of 6 Gy neutron beam plus liposomes did not show any normal
tissue response including skin. Hair loss and reddened, scaled skin in the radiation field
were observed in some mice for which tumors were controlled in the group having
liposome-mediated BNCT with 8 Gy neutron beam. In BPA-mediated BNCT, hair loss and
reddened skin were produced by 6 Gy neutron beam irradiation. One of these tumor-
controlled mice was sacrificed due to serious skin damage, moist desquamation, about 1
month after the irradiation. Moist desquamation was also observed in all mice irradiated
with 20 Gy and 30 Gy X-rays.
Moreover, 8 Gy neutron beam irradiation in the presence of BPA resulted in all mice
dying because of gastrointestinal (GI) damage. At 6 days after irradiation, one of these mice
was found dead, and all other mice showed a poor body condition and traces of diarrhea.
Histology studies of these sick mice confirmed that there was GI damage. These results
verify a lower toxicity of liposomes for normal tissues (especially, for skin and gut), which
could be advantageous in the clinical use if better tumor distribution could be realized.
Thus, even though a T/B ratio is an important criterion for evaluation of a new boron
compound, the effect of each particular boron compound on normal tissues must be
examined.
Liposome solutions were supplied in small volumes and limited the number of mice
used for therapy studies. Moreover, biodistribution studies had to be carried out using
different batches of liposome solution. These experiments often did not agree completely
even after the data were normalized to the same injected dose. This inconsistency could be
explained by the different size of liposomes in each batch (59-70 nm). For example, the
size of liposomes was given as an average diameter, 71.9 nm, with the size distribution
from -55 to -85 nm. As liposomes injected i.v. are susceptible to recognition by
monophagocytes in the reticuloendothelial system, liposomes with the size <70 nm or >300
nm accumulate in liver and spleen and liposomes with the size of 100-200 nm are favorable
for longer circulation in the blood [101]. Another study showed that liposomes with
diameters of 90-200 nm stayed longer in the blood and accumulated more in the EMT-6
tumor than those with 40 nm or >200nm [102]. The average size of most MAC-16 and
MAC+TAC liposome batches in these studies was 70 nm, which is near the size that is
trapped in the liver and the pharmacokinetics may therefore be very sensitive to the actual
size distribution in a batch.
For in vivo evaluation of a new compound especially whose characteristic in various
batches would affect the study, one large quantity of compound should be used in a
complete biodistribution including microdistribution and therapy studies. If a single batch
production is not possible, then quality assurance on compound production needs to be
considered. When a new compound sufficiently accumulates in the tumor, the homogeneity
of microscopic 10B distribution must be examined. Then, the therapeutic effectiveness of
this compound would be studied including the normal tissue response.
3-5. Summary
Boronated liposome formulations (MAC-16 and MAC+TAC) were evaluated in vivo
with the EMT-6 murine mammary carcinoma. Biodistribution studies showed high '0B
uptake in tumor (20-40 [tg l0B/g) at 30 hours after an i.v. injection. Tumor control
experiments were performed using the thermal neutron beam to compare the efficacy of the
boron delivered by liposomes with that by BPA. Irradiations were carried out at optimized
times of 30 (liposomes) and 4 hours (BPA) after injection. The MAC-16 formulation
produced long-term (120 days) tumor control with the liposomes of 16 % whereas BPA
controlled 63 % for similar tumor boron concentrations (approximately 20 tg l0B/g) and
the same neutron beam dose. Microscopic distribution studies using fluorescent markers
revealed non-uniform 1oB distribution in the tumor from the liposomes which were
concentrated at the edge of the EMT-6 tumor. These results were independently confirmed
using HRQAR that also showed uniform boron distributions with BPA. Therefore, in vivo
evaluation characterized the uptake and retention properties of liposomes for a single
injection but these appear inferior to BPA in the tumor studies performed with the EMT-6
tumors.
CHAPTER FOUR
POSSIBLE IMPROVEMENTS IN THE USE OF
BORONATED LIPOSOMES
4-1. Introduction
Previous study of boronated liposomes using the EMT-6 tumor model showed no
therapeutic effectiveness of BNCT, despite a sufficient gross loB uptake (20-40 gg 10B/g) in
EMT-6 tumor. The major reason for this unsatisfactory outcome appeared to be
inhomogeneous microscopic distribution of 10B in the tumor. This chapter describes studies
to evaluate the effectiveness of boronated liposomes in a different tumor model and to try
and improve the effectiveness by increasing the injection volume of boron.
As a different tumor model, the SCCVII mouse squamous cell carcinoma was chosen
as a model for head and neck cancer. Head and neck tumors are difficult to treat
successfully with conventional therapy because this tumor region is close to radiosensitive,
critical organs such as central nervous system, oral mucosa, and skin. Therefore, the
selective tumor targeting ability of BNCT could be beneficial for the treatment of these
tumors. As a first step, a biodistribution study was carried out to measure how much boron
was delivered by boronated liposomes to tumor, blood, liver and skin as a function of time
after liposome injection. Since we learned its significance, the microscopic distribution of
10B in the tumor was also examined.
A multiple-injection method was applied for increasing the total injected dose of
liposomes because of the limited capacity (volume) for each injection. This approach has
produced high tumor boron concentrations with several types of boron compounds which
have the characteristics of long retention in tumor, such as porphyrins and liposomes [45,
103, 104]. Biodistribution and microscopic distribution studies following double injection
of liposomes were performed using the MAC+TAC liposome solution and the EMT-6
tumor model.
4-2. Alternative tumor model - SCCVII tumor
4-2-1. Materials and methods
4-2-1-1. Tumor model
The SCCVII mouse squamous cell carcinoma was used as a tumor model of head and
neck cancer. SCCVII cell line (generously provided by Brookhaven National Laboratory)
was grown in Dulbecco's Modification of Eagle's Medium (DMEM, Mediatech)
supplemented with 10 % fetal bovine serum (SeraCare Life Science), 1 % 200 mM L-
glutamine (Mediatech), and 1 % 5,000 I.U./ml penicillin - 5,000 gg/ml streptomycin
(Mediatech) at 37 'C in an atmosphere of 5 % CO 2. Cells were used for transplantation
when the monolayer reached -90 % confluence. Each female C3H mouse was anesthetized
with isoflurane, and then 2x10 6 SCCVII cells in a volume of 0.1 ml were injected
subcutaneously on the lower back.
4-2-1-2. Liposome solutions
Liposome solutions were provided in batches of -7-10 ml. Each batch had different
boron concentration that varied from 425 to 600 in [g 10B/ml for MAC-16 solutions and
from 1160 to 1780 in [g loB/ml for MAC+TAC solutions. Liposome mean diameter varied
from 59-76 nm. The injected doses are indicated in each table and graph. Thus, for some
biodistribution studies, different batches of liposome solutions were used and where these
data were combined results were scaled by the ratio of solution loB concentrations.
4-2-1-3. Biodistribution study
Murine biodistribution studies used female C3H mice (22-30 g) with SCCVII tumors
implanted subcutaneously on the lower back about 2-3 weeks before the experiments. Each
mouse received an injection of 0.2 ml into the retro-orbital sinus while under brief
isoflurane anesthesia. Three to five tumor-bearing mice were euthanized at each time point
by isoflurane overdose. Blood was removed directly from the heart, and tumor, liver, and
skin were collected for boron analysis. Tumor mass at the time of harvesting was 100-300
mg.
Based on the experience of our earlier liposome biodistribution studies with the
EMT-6 tumor, the initial liposome biodistribution study was performed at a single time of
30 hours after retro-orbital injection of 10B enriched liposome solutions. After that,
experiments using unenriched liposome solution were carried out for additional sacrifice
times of 6 and 24 hours after injection. Finally, a complete biodistribution study for
sacrifice times of 6, 24, 30, 48, 54, and 72 hours was accomplished with one large batch of
unenriched liposome solution.
A BPA biodistribution study was also performed for comparison. BPA was injected
intraperitoneally (i.p.) as the BPA-fructose complex (BPA-F) to improve solubility. Tumor
and blood samples were taken at 1, 3, and 5 hours after administration.
4-2-1-4. Boron analysis
The initial biodistribution study used PGNAA in the MITR-II to measure
macroscopic 'oB concentrations in blood and other tissue samples. Unlike blood and liver
samples, tumor and skin samples could not be measured with PGNAA because of their low
l'oB concentrations which were below the detection limit of PGNAA. PGNAA was also
used for measuring the 10B concentration of blood and tumor samples following BPA-F
injection.
Since samples had low 10B concentrations in both the initial study and in the studies
using unenriched liposomes, total boron (l0B + IIB) concentrations were measured by using
inductively coupled plasma optical emission spectroscopy (ICP-OES). ICP-OES has a
lower detection limit that is practically limited to 0.1 pg B mainly because of the dilutions
necessary during sample preparation with acid. Durin ICP analysis, blood was mixed with
the same volume of a 2.5 % solution of the detergent Triton X-100. Then, the blood slurry
was diluted to ten times the original blood volume with distilled water in order to obtain
enough volume for multiple measurements. Tissues (< 200 mg) were digested in 0.6 ml of a
1:1 mixture of nitric and sulfuric acids and 2 ml of a 10 % solution of Triton X-100. The
tissue samples were then diluted to 6 ml with distilled water in order to obtain a clear
solution and enough volume for multiple measurements. The prompt gamma and ICP
100
analysis methodologies were cross calibrated and analysis of blood samples using both
methods produced values that agreed to within 10 %.
4-2-2. Results
4-2-2-1. Liposome biodistribution study
Table 4.1 shows loB concentrations measured by PGNAA in tumor, blood, liver, and
skin at 30 hours after l'B-enriched MAC-16 and MAC+TAC solution administrations. The
average boron concentration of 6.9 pg '0B/g of tumor was found in the SCCVII tumor when
using MAC-16. This was much less than the required boron concentration of at least 20-30
pIg l'oB/g of tumor for a promising boron compound. MAC+TAC administration roughly
raised the l'oB concentration to 23.4 pg l'oB/g of tumor; however, this amount was only half
of that for the EMT-6 tumor. Boron concentrations were analyzed at other time points, 6
and 24 hours after unenriched MAC-16 and MAC+TAC solution injections (Table 4.2).
Figures 4.1 and 4.2 exhibit the combination of two experiments. To combine these
two experiments that used different liposome solutions, the boron concentrations of the 6-
and 24-hour time points were scaled up by the ratio of injection doses (i.d.) a factor of 1.4
for both MAC-16 and MAC+TAC. Slow tumor uptake and rapid blood clearance for MAC-
16 and MAC+TAC were observed in Figures 4.1 and 4.2. However, the curves were not
smooth even when the data were normalized. To check whether longer times may be better
for therapy, a complete biodistribution was planned.
Table 4.1. 10B concentrations measured with PGNAA for 30 hours after retro-orbital
injection of MAC-16 (enriched l0B, i.d. = 4.6 pg l'oB/gbw) and MAC+TAC (enriched l'oB,
i.d. = 12.3 gg l'oB/gbw). Results are expressed as the mean ± SD for 5 mice bearing
SCCVII tumors.
0oB concentration (kg loB/g)
Liposomes
Tumor Blood Liver Skin
MAC-16 6.9 ± 1.5 12.0± 1.7 12.4 ± 0.6 3.8 0.4
MAC+TAC 23.4 ± 10.5 63.0 ± 7.2 46.1 ± 5.2 10.0 ± 2.1
Table 4.2. Total boron concentrations measured with ICP-OES for 6 and 24 hours after
retro-orbital injection of MAC-16 (unenriched B, i.d. = 3.3 jIg B/gbw) and MAC+TAC
(unenriched B, i.d. = 8.9 jLg B/gbw B). Results
bearing SCCVII tumors.
are expressed as the mean ± SD for 5 mice
B concentration (jLg B/g)
Liposomes Time (hrs)
Tumor Blood Liver Skin
6 1.7 ± 0.6 21.5 + 1.8 22.8 ± 2.1 1.6 0.2
MAC-16
24 2.7 ± 1.2 8.7 + 1.3 10.4 ± 2.2 2.3 ± 0.2
6 4.6 ± 1.4 67.6 + 5.2 43.9 ± 2.9 3.4 ± 1.5
MAC+TAC
24 6.1 + 1.7 39.4 ± 5.2 39.3 ± 3.1 6.7 ± 1.8
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Figure 4.1. Total boron concentrations (ig B/g) versus time (hours) for MAC-16 injection
into the retro-orbital sinus with a dose of 4.6 jig B/gbw. The 6-and 24-hour time points
were scaled up by the ratio of injected boron dose, 1.4. Total boron concentration
represents either total boron measured by ICP-OES or enriched '0B measured by PGNAA.
Points represent the mean ± SD for 5 mice bearing SCCVII tumors. Lines are drawn
connecting the data to help guide the eye.
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Figure 4.2. Total boron concentrations (pg B/g) versus time (hours) for MAC+TAC
injection into the retro-orbital sinus at a dose of 12.3 Rg B/gbw. The 6-and 24-hour time
points were scaled up by the ratio of injected boron dose, 1.4. Total boron concentration
represents either total boron measured by ICP-OES or enriched 10B measured by PGNAA.
Points represent the mean ± SD for 5 mice bearing SCCVII tumors. Lines are drawn
connecting the data to help guide the eye.
A complete biodistribution study in mice bearing SCCVII tumors was carried out
using an unenriched liposome solution and boron analysis by ICP-OES. Figure 4.3 and
Table 4.3 show total boron concentrations measured by ICP-OES in SCCVII tumor, blood,
liver, and skin as a function of time after injection of MAC-16 with a dose of 3.7 pg B/gbw.
The maximum boron concentration in tumor was only 6 jg B/g at 24-30 hours after MAC-
16 administration. This is far below the amount of boron needed to give enough dose in
tumor during BNCT. Boron in blood and liver showed good clearance, but boron
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Figure 4.3. Total boron concentrations (pg B/g) versus time (hours) for MAC-16 with retro-
orbital injection with a dose of 3.7 [tg B/gbw. Points represent the mean ± SD for 3-4 mice
bearing SCCVII tumors. Total boron concentrations were measured by ICP-OES. Lines are
drawn connecting the data to help guide the eye.
Table 4.3. Total boron concentrations measured by ICP-OES for different times after
MAC-16 retro-orbital injection with a dose of 3.7 [lg B/gbw. Results
mean ± SD for 3-4 mice bearing SCCVII tumors.
are expressed as the
Time after MAC-16 B concentration (gg B/g)
administration (hrs) Tumor Blood Liver Skin
6 4.6 ± 0.6 36.2 ± 2.8 21.7 ± 3.6 2.5 0.4
24 6.1 + 0.9 15.2 ± 1.7 17.7 ± 1.6 5.2 ± 0.6
30 6.0 ± 1.8 11.4 ± 3.0 16.9 ± 1.3 6.4± 2.7
48 5.4 ± 1.1 5.5 ± 0.4 10.9 + 1.5 6.0 ± 1.4
54 5.0 + 0.7 4.7 ± 0.5 11.8 ± 1.0 5.0± 1.4
72 3.7 ± 0.1 2.9 ± 0.3 7.2 ± 0.8 4.6 ± 0.9
104
Figure 4.4 and Table 4.4 represent the total boron concentration in SCCVII tumor,
blood, liver, and skin through the time course after administration of MAC+TAC with an
injected dose of 9.6 tg B/gbw. Boron concentration in SCCVII tumor was maximized at 24
hours as only 9 gg B/g, while blood showed rapid clearance. However, tumor boron
concentrations from both liposomes are too low to give successful tumor therapeutic
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Figure 4.4. Total boron concentrations (jg B/g) versus time (hours) for MAC+TAC with
retro-orbital injection dose of 9.6 gg B/gbw. Points represent the mean + SD for 5 mice
bearing SCCVII tumors. Total boron concentrations were measured by ICP-OES. Lines are
drawn connecting the data to help guide the eye.
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Table 4.4. Total boron concentrations measured by ICP-OES for different times after
MAC+TAC retro-orbital injection with a dose of 9.6 Rg B/gbw. Results are expressed as
the mean + SD for 5 mice bearing SCCVII tumors.
Time after MAC+TAC B concentration (jig B/g)
administration (hrs) Tumor Blood Liver Skin
6 6.8 ± 0.8 57.8 + 4.9 71.3 ± 6.7 4.7 + 0.8
24 9.1 ± 2.1 27.7 + 6.2 52.8 ± 5.7 8.4 + 1.5
30 6.6 + 0.4 17.0 ± 1.5 57.2 ± 1.4 8.2 + 0.9
48 6.2 + 1.2 5.3 + 0.8 45.9 ± 4.6 12.4 + 1.0
54 6.7 + 0.7 4.2 ± 0.7 52.1 ± 3.8 9.4 + 1.5
72 4.1 + 1.5 2.7 + 0.3 32.8 ± 4.3 7.7 + 1.7
4-2-2-2. BPA biodistribution study
Table 4.5 and Figure 4.5 show the 'oB concentrations in tumor and blood as a
function of time after BPA-F injection at a dose of 43.0 kg l0B /gbw. BPA which is a small
molecule showed fast blood clearance and fast tumor uptake. The average loB
concentration in tumor at 1 hour after BPA-F i.p. injection was 23.8 gg 1oB/g.
Table 4.5. 10B concentrations at different times after BPA-F i.p. injection of 43.0 kg 1oB
/gbw. Results are expressed as the mean ± SD for 5 mice bearing SCCVII tumors. 1oB
concentrations were measured by PGNAA.
Time after BPA-F
administration (hrs)
l0B concentration (kg loB/g)
Tumor Blood
23.8 + 3.0 15.3 ± 2.9
18.1 + 4.3 11.3 + 1.8
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Figure 4.5. 1oB concentrations (ptg loB/g) measured by PGNAA versus time (hours) after
BPA-F i.p. injection at a dose of 43.0 gg l0B /gbw. Points represent the mean + SD for 5
mice bearing SCCVII tumors. Lines are drawn connecting the data to help guide the eye.
4-3. Multiple injections of MAC+TAC in the EMT-6 tumor model
4-3-1. Materials and methods
4-3-1-1. Tumor model
The murine mammary carcinoma EMT-6 was used as a tumor model of breast cancer.
The EMT-6 cell line (kindly provided by Brookhaven National Laboratory) was grown in
Dulbecco's Modification of Eagle's Medium (DMEM, Mediatech) supplemented with
10 % fetal bovine serum (SeraCare Life Science), 1 % 200 mM L-glutamine (Mediatech),
and 1% 5,000 I.U./ml penicillin - 5,000 gg/ml streptomycin (Mediatech) at 37 'C in an
atmosphere of 5 % CO2. Cells were used for transplantation when the monolayer reached
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-90 % confluence. Each female BALB/c mouse was briefly anesthetized with isoflurane,
and then 106 EMT-6 cells in a volume of 0.1 ml were injected subcutaneously on the lower
back.
4-3-1-2. Biodistribution study
Murine biodistribution studies used female BALB/c mice (18-20 g), with EMT-6
tumors implanted subcutaneously on the lower back at 10 days before the experiments. 'oB-
enriched MAC+TAC solution (0.2 ml) was injected into the retro-orbital sinus of each
mouse which was under brief isoflurane anesthesia. Two hours after the first injection, 0.2
ml of MAC+TAC solution was administrated into the other eye for the second injection. At
the sacrifice time, which was 30 hours after the first injection, the mice were euthanized by
isoflurane overdose. Blood was removed directly from the heart, and tumor, liver, and skin
were collected for boron analysis. Tumor mass at the time of sacrifice was 100-250 mg. 1oB
analysis for blood and tissues was carried out using PGNAA in the MITR-II.
4-3-1-3. Tumor therapeutic response study
Therapeutic response was evaluated in female BALB/c mice (18-21 g) bearing EMT-
6 tumors implanted subcutaneously on the back at 10 days prior to the experiments.
Thermal neutron beam irradiations were performed using the vertical M-011 thermal
neutron beam of the MITR-II. Thermal neutron beam doses of 6 Gy were given to tumors
on 8 mice at 30 hours after the first injection of the MAC+TAC double injections and to 6
mice with the beam only. Due to concerns over the high concentrations of '0B in blood and
liver resulting from double injections, 6 Gy was chosen as a reasonable dose in order to
reduce the possibility of a severe normal tissue response or even death. To evaluate the
tumor response, tumor volume was measured daily for 2 weeks after irradiations. After this
2-week period, tumor volume was measured 2-3 times per week. Tumor volume was
calculated from orthogonal length and width measurements using the formula for an
ellipsoid V = (ab2)/2, where a is the larger of the two diameters. Mice were sacrificed if the
tumor became necrotic or its volume exceeded 500 mm3. If the tumor was controlled, mice




Boron concentrations in the EMT-6 tumor, blood, liver, and skin were measured 30
hours after the first injection (Table 4.6 and Table 4.7). Total injected doses were 25.6 pg
'lB/gbw for the first experiment shown in Table 5.6 and 37.5 pg 'OB/gbw for the second
experiment shown in Table 4.7. A tumor therapeutic response study was included in the
second experiment. Thus, Table 4.7 represents loB concentrations in tumor, blood, liver,
and skin at the time of thermal neutron beam irradiation. Double injection of the
MAC+TAC liposome solution produced -50 pg loB/g of 'lB concentration in tumor, which
is a sufficient amount of boron to expect tumoricidal effect. IoB concentrations in blood and
liver were also almost doubled compared to the single injection. Also, 'lB concentration in
skin was significantly above the PGNAA detection limit while single injection of
MAC+TAC produced a loB concentration in skin that was below the PGNAA detection
limit.
Table 4.6. '0B concentrations measured by PGNAA for 30 hours after the first of two retro-
orbital injections of MAC+TAC (12.8 gg loB/gbw per injection). The interval between the
two injections was 2 hours and the total injected dose was 25.6 jg 'oB/gbw. Results are
expressed as the mean ± SD for 3 mice bearing EMT-6 tumor.
MAC+TAC l0B concentration (gg loB/g)
double injection Tumor Blood Liver Skin
51.0 + 4.6 92.5 ± 21.8 107.6 ± 7.0 4.5 ± 0.8first injection
Table 4.7. 'oB concentrations measured by PGNAA for 30 hours after the first of two retro-
orbital injections of MAC+TAC (18.7 gg l'oB/gbw per injection). The interval between the
two injections was 2 hours and the total injected dose was 37.5 gg l'oB/gbw. Results are
expressed as the mean ± SD from 4 mice for blood, liver, and skin and from 2 mice for
EMT-6 tumor.
MAC+TAC l'oB concentration (jg 'oB/g)
double injection Tumor Blood Liver Skin
30hoursafterthe 52.7 ± 0.1 115.4 ± 16.0 127.9 ± 7.3 6.1 ± 1.8
first injection
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4-3-2-2. Tumor therapeutic response study
Table 4.8 summarizes the fraction of tumors controlled for the two treatment groups.
Neutron beam irradiation alone (6 Gy) did not control any tumors. On the other hand, 6 Gy
neutron beam irradiation with MAC+TAC double injection controlled 4 tumors out of 6
tumors in mice. Initially 8 mice were irradiated following MAC+TAC double injection, but
2 mice died at 7 days after irradiation. The reason of death was indeterminate, but was not
from the tumor growth because the mice were found dead; there had been no signs of
worsening body condition or diarrhea prior to day 7. However, because the time of death
was close to the onset time of gastrointestinal (GI) injury, it could be from the GI syndrome.
Neither treatment produced any evident normal tissue response. Mice in the 6 Gy beam
irradiation with MAC+TAC double injection showed only a very minor hair loss over the
whole body during 2 weeks after irradiation, despite the high '0lB concentrations in blood,
liver, and skin. Some mice showed hair loss in the irradiated field. There was no redness of
skin which was clearly shown during BNCT irradiation with BPA (Chapter 3).
Table 4.8. Fractions of EMT-6 tumors controlled with different treatments.
Treatment Fraction of tumors controlled
6 Gy neutron beam 0/6 (Figure 4.6)
6 Gy neutron beam + MAC+TAC double injection 4/6* (Figure 4.7)
* 2 early deaths were censored.
Figure 4.6 and 4.7 represent measured tumor volumes of each mouse following 6 Gy
neutron beam irradiation with and without double injections of MAC+TAC beginning 30
hours prior. Both groups show tumor growth delay post-irradiation but with different
recovery rates. In the 6 Gy neutron beam alone group, growth suppression was initially
maintained for -6-7 days post-irradiation, but the tumors were quick to recover there after.
This result is consistent with earlier 6 Gy neutron beam only irradiations described in
Chapter 3. A much longer growth suppression period of -26-28 days post-irradiation was
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Figure 4.6. EMT-6 tumor volume (mm3) versus time (days) after 6 Gy neutron beam
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Figure 4.7. EMT-6 tumor volume (mm3) versus time (days) after 6 Gy neutron beam
irradiation at 30 hours after 1st injection of MAC+TAC double injections. Each line
indicates the tumor volume for an individual mouse.
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Figure 4.8. Mouse survival (%) as a function of time after EMT-6 tumor irradiation with 6
Gy thermal neutron beam alone (n= 14), 6 Gy thermal neutron beam in the presence of
MAC (n=19), MAC+TAC (single (n=8) and double (n=6) injections), and BPA (n=8). A
control group of mice bearing EMT-6 tumors (n=7) received no irradiation. Approximate
10B concentrations in the tumor at the time of BNCT are indicated in the Figure.
Figure 4.8 illustrates the mouse survival percentage as a function of time after
irradiation with 6 Gy thermal neutron beam alone, 6 Gy thermal neutron beam in the
presence of MAC, MAC+TAC (single and double injections), and BPA. Approximate loB
concentrations in the tumor at the time of BNCT were 20 jig loB/g from MAC and BPA, 40
ag 10B/g from a single injection of MAC+TAC, and 50 gg loB/g from a double injection of
MAC+TAC. The survival following 6 Gy neutron beam alone was obtained by combining
the results of this experiment (Figure 4.6; n = 6) and the first experiment (Figure 3.6; n = 8).
With the same 6 Gy neutron beam dose, double injections of MAC+TAC showed a
superior mouse survival (66.7 %). Here, two mice in the 6 Gy with MAC+TAC two
injections that died of unknown cause at day 7 were excluded as they possibly died from
side effects related to the experiment.
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4-4. Discussion
As described in Chapter 3, liposome-based BNCT in the EMT-6 tumor model had
little effect. The primary reason was believed to be the poor microscopic distribution of 10B
in the tumor at the time of therapy. Two approaches were taken to further explore the
potential usefulness of liposomes for BNCT: 1) To determine if the poor microscopic boron
distribution was unique to the EMT-6 model, a biodistribution study was carried out in
another tumor model; the SCCVII mouse squamous cell carcinoma. 2) A modified injection
protocol was used in an attempt to increase the '01B concentration and uniformity of uptake
in the EMT-6 tumor model.
As an alternative, the SCCVII mouse squamous cell carcinoma was used, which is a
well-established tumor model for head and neck cancer. Variable results were obtained
from the different uptake studies that used different batches of liposomes. In the complete
time study, boron uptake was measured at between 6-72 hours after injection. The
maximum boron concentration in tumor achieved with MAC+TAC was only 9.1 pg B/g
after 24 hours. This maximum tumor boron concentration is a third of the blood boron
concentration and this trend is consistent in another study using '01B-enriched liposomes.
MAC-16 or MAC+TAC liposomes did not produce enough '01B uptake in the SCCVII
tumor, which was less than the requisite boron amount for BNCT (20-30 Rg B/g) and
especially less than in the EMT-6 tumor. Therefore, further study was not warranted in this
tumor model.
The EMT-6 and SCCVII tumors showed different uptake of liposomes. Since
liposomes accumulate in the tumor via tumor leaky vasculature, a higher boron uptake can
be observed in the well-vascularized tumors. These two tumors are poorly-vascularized,
solid animal tumors, which commonly consist of hypoxic cells [105]. The EMT-6 tumors
generally contain larger necrotic area and hypoxic cells than the SCCVII tumors [106]. The
histology sections showed an apparent necrotic region in the EMT-6 tumors even with a
small diameter of approximately 5 mm. The hypoxic fraction of tumor increases with
increasing tumor size. With the tumor size of 5-10 mm, which is the range for our studies,
the EMT-6 tumor has relatively higher hypoxic fraction (5-20 %) than the SCCVII tumor
(1-10 %) since the EMT-6 tumor grows faster than SCCVII tumor [107]. This histology
information suggests that the SCCVII tumor would be a better tumor model in the use of
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liposomes. However, the SCCVII tumor showed much less boron uptake than the EMT-6
tumor, so there must be other explanations. The vasculature permeability of these two
tumors could be different, which could affect passage of the liposomes and consequently
result in different boron uptake in the tumor. Blood and liver showed relatively faster
clearance in C3H mice bearing SCCVII tumors, which could indicate less 10B is available
to accumulate in the tumor. loB accumulation in the skin for the SCCVII tumor model,
which used C3H female mice, was much higher (maximum ['0B] = -13 pg loB/g from
MAC+TAC) than for the EMT-6 tumor model using BALB/c female mice whose skin
showed undetectable boron uptake by PGNAA.
The EMT-6 tumor showed sufficient boron uptake but had poor microscopic boron
distribution. Since each injection volume was limited to 0.2 ml, a multiple-injection method,
which increased the total injection dose, was applied in an effort to improve microscopic
distribution. As a pilot study, a simple protocol, a double injection with a 2-hour interval
between injections with the EMT-6 tumor, was evaluated in a single experiment. This
produced approximately 50 pg 1oB/g in the EMT-6 tumors, which was almost twice the
desired boron concentration. IoB concentrations in blood and liver were also relatively high;
over 100 pg l0B/g.
Initially 8 mice bearing EMT-6 tumors were irradiated after two injections of
MAC+TAC, but 2 mice died at 7 days after irradiation. This death was not from the tumor
overgrowth. However, there was no obvious evidence of death such as diarrhea by GI
damage, and it was not possible to perform histology study in gut, bone marrow, or liver to
determine the reason for death because mice were found dead in their cage. All mice which
received a double injection lost from 2 to 4 g of their body weight (10-20 % of total body
weight) within 6 days after the irradiation. Both dead mice lost 4 g of body weight a day
before dying. The fact that the time of death (7 days after irradiation) would imply the
death could be from GI damage since the GI syndrome generally occurs at 5-6 days after
the irradiation. Another explanation might be liver toxicity, because part of liver was in the
irradiation field and 10B concentration in liver was around 130 gg l0B/g. Even though the
neutron flux is attenuated at the depth of liver, boron dose may nevertheless be significant
and cause some damage. Irradiations following a single injection of MAC+TAC did not
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cause deaths other than tumor overgrowth with boron concentrations in blood and liver of
51 and 76 pg 10B/g, respectively.
Minor hair loss over the whole body was observed from mice irradiated with 6 Gy of
neutron beam following a double injection of MAC+TAC, but it recovered in 2 weeks after
irradiation. The irradiated area of each mouse was shaved at the time of implanting tumor
cells, but hair on some mice did not regrow after irradiation for several weeks. All mice in
which tumors were controlled had fully regrown hair on their back in about 4 weeks. There
was no other apparent skin damage such as redening. In BPA-mediated BNCT from
Chapter 3, one of these mice showed severe moist desquamation at 3-4 weeks after
irradiation [108]. On the other hand, in all liposome-mediated BNCT using MAC-16 and
MAC+TAC even with a double injection, there was no obvious skin damage. This could be
an advantage of using liposomes.
The tumor response study controlled 4 EMT-6 tumors out of 6 (66.7 % tumor
control). Here, two mice that died on day 7 probably from GI damage were not included in
the survival graph. An improved tumor response from the double liposome injection could
be from increased overall boron concentration in the tumor. Since sufficient amounts of
boron accumulated at the edge parts of the tumor, this could kill all the tumor cells at the
edge and could lead to an absolute lack of blood and oxygen supply to the middle part of
tumor which already consists of many necrotic cells. This condition could control tumor,
especially for a small size of tumor. Another possible explanation for improved tumor
response could be the synergetic effect of damages on tumor cells and tumor vasculature.
High boron accumulation in blood can cause a significant damage on tumor vasculature
along with the direct damage on tumor cells from boron present in tumor. A more uniform
distribution of boron in the tumor was anticipated, but the HRQAR image (Figure 4.9) from
a double injection of liposomes shows that although more boron is taken up in the EMT-6
tumor (as measured by PGNAA) the overall distribution is still highly non-uniform. Further
investigation is suggested for understanding the mechanism of improved therapy response.
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Figure 4.9. HRQAR image of the EMT-6 tumor that received a double MAC+TAC injection to visualize boron-neutron capture
particle tracks (black dots) superimposed on the histology. Red circles highlight areas of concentrated tracks. More boron is taken
up in the EMT-6 tumor, but the overall distribution is still highly non-uniform. Scale bar: 200 pm for the left and 20 [tm for the
middle and right panels that are magnified portion of the identified insets A and B. (HRQAR image produced by Dr. Kent Riley.)
Concerning the safety of this high 10B concentration in blood, the responses of central
nervous system (CNS) to BSH using a rat spinal cord model were reviewed due to the
similar behavior in the CNS of liposomes and BSH because of their large size [108, 109].
The model for the CNS was the rat spinal cord irradiated at BMRR with a boron
concentration in blood, approximately 100 gg l'oB/g. The endpoint was limb paralysis
within 7 months. Effective doses for 50 % paralysis (EDs5o) were 24.9 Gy of boron dose and
5.4 Gy of beam dose in the neutron beam with BSH group [109]. Since the quality of beam
was different between the MITR-II and the BMRR, the RBE values of the beam were
different: 1.2 at the MITR-II for rat lung irradiation [89] and 1.4 at the BMRR for rat spinal
cord irradiation [109]. The same CBE value, 0.46, for CNS response could be applied to
both BSH and liposomes due to their similar behavior in the CNS. Using these data and
ED 50 (boron dose = 25.7 Gy) determined for the MITR-II thermal neutron beam, the
maximum boron concentration in blood before the onset of serious CNS response would be
35 gg loB/g at the beam dose of 6 Gy. Therefore, if this double injection protocol was
applied to tumor which contained spinal cord in the irradiation field, it would cause severe
CNS response.
The same type of analysis for liposomes can be applied to the skin response by
comparing with BSH. Using the information of the RBE of the BMRR beam (3.5), ED5 0 for
moist desquamation in the skin response (47.86 Gy BMRR beam), and the CBE for skin
response (0.55) [108], the maximum boron concentration in skin to avoid serious skin
response would be 87 jg "oB/g with 6 Gy of the MITR-II thermal neutron beam dose.
When BSH was injected in rats, boron concentrations in blood and skin (-80 pg 'OB/g)
were comparable between 30 minutes and 2 hours after injection [108]. However, boron
concentrations in skin delivered by liposomes remained below 10 gg IoB/g at all time points
with a double injection. This is a major difference between liposomes and BHS and
indicates that liposomes can be much safer than BSH in the skin.
This double injection experiment was a single pilot study using only a few animals.
Considering the promising result of this experiment, the administration for multiple
injections could be modified for further improvement of the use of liposomes. Several
injections of liposome solution delivered after the blood has cleared would achieve even
higher '0B concentration in the tumor due to a long retention there and low boron
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concentrations in the blood and liver. Since the EMT-6 tumor grows relatively rapidly,
loaded boron from multiple injections might be diluted by an enlarged tumor size over the
period of several days. A simple estimation can be used to simulate the boron concentration
in tissues after the multiple-injection. The boron concentration profile from a single
injection can be shifted with the interval of the injection time and then the boron
concentration of each time point can be added. This estimation for a double injection with
2-hour-interval agreed well for boron concentration of tumor and liver but not for blood.
Blood boron concentration was measured as ~50 % higher than the estimation, which
suggests that high boron concentration in blood or liver may affect boron clearance from
blood. This estimation using a single injection profile of MAC-16 liposome solution with
the EMT-6 tumor showed low boron concentration in the blood and liver (< 50 [tg loB/g)
and high boron concentration in the tumor (-90 gg IoB/g) at 70 hours after 1 st injection
when MAC-16 solution was injected 6 times every 4 hours over 2 days. Even though blood
boron concentration may be underestimated, this can be a safer and more effective protocol





This project developed a radiobiological assay for testing new boron compounds with
the aim of identifying promising new compounds to help optimize and improve the
effectiveness of BNCT. An in vitro evaluation methodology was developed to enable the
efficacy of a boron compound to be determined during the early stages of its development
and which is consequently available in only limited quantities (less than a milligram of l0B).
A colorimetric assay and 96-well plates were applied to minimize the quantity of
compound required for testing and was optimized for the murine SCCVII, squamous cell
carcinoma to determine the chemical toxicity and relative cellular uptake by comparison
with reference compounds, boric acid and BPA. Chemical toxicity testing revealed a test
compound, BOPP, was toxic over concentrations of 10 pg 10B/ml that was considered an
upper limit of acceptability during testing so as not to mask radiation induced damage. Cell
irradiations were performed using the thermal neutron beam at MITR-II and survival curves
for different compounds were compared at concentrations of approximately 5 lag 10B/ml for
each compound. Using less than 300 jtg of BOPP, and 250 kVp X-rays as control
irradiations, a compound biological effectiveness (CBE) of 3.3 + 0.7 was determined for
BOPP. A comparable result (3.5 ± 0.5) was obtained for boric acid whereas BPA was
significantly higher (6.1 + 0.7). These CBEs reflect the relative intracellular accumulation of
'
0B: similarly low for BOPP and boric acid, higher for BPA. A comprehensive uncertainty
analysis for the CBE value yielded an uncertainty of 10-20 %. Thus, when general CBE
factor is applied to another study for the same endpoint using a different biological system
(i.e. humans), this large uncertainty must be recognized as a major source of experimental
error especially for a study in which the dose-response relationship is steep and a slightly
different dose could cause a large change in outcome.
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Boronated liposomes have shown a sufficient boron uptake for therapeutic BNCT in
the EMT-6 murine mammary carcinoma model that warranted further evaluation with a
therapy study. This had not been performed before. In this thesis, boronated liposomes were
evaluated for the first time with tumor therapy experiments using the EMT-6 tumor model.
Results of earlier biodistribution studies were confirmed and similar boron uptake in the
tumor (approximately 20 gg 10B/g) was observed with MAC-16 liposomes and BPA, one of
the two boron compounds approved for clinical trials of BNCT in the USA. However, the
tumor control in mice for the EMT-6 tumor from BPA was superior (62.5 %) to that from
MAC-16 liposomes (15.8 %). Microscopic distribution studies using fluorescent-labeled
liposomes and HRQAR exhibited a non-uniform microscopic distribution of boron
delivered from liposomes in the tumor at the time of therapy and explains the lack of
therapeutic effect. This underlines the importance of a boron distribution at a microscopic
level. Further exploration of the potential usefulness of liposomes was attempted by using
another tumor model, the SCCVII mouse squamous cell carcinoma. Insufficient boron
uptake in the SCCVII tumor was shown in the biodistribution study with liposomes and no
further investigation was performed. Animal irradiations following a double injection of
MAC+TAC liposomes were performed as a pilot study. Double injection of MAC+TAC
liposomes did not improve the observed homogeneity of '0B within the tumor, but an
enhanced therapeutic effect (comparable to BPA-based BNCT) was obtained that is mainly
attributed to higher '0B concentration from the increased injected dose of the compound.
5-2. General concepts for evaluating boron compounds
The best method for evaluating new boron compounds depends upon their stage of
development as well as their mechanism for selective tumor uptake. Since boron
compounds are often synthesized in small quantities at early stages of development,
applying an in vitro screening method is often advantageous. If the boron compound has to
be tested in a specific cell line that for example express a particular enzyme, the protocol
for the colorimetric assay must first be optimized especially for initially plated cell density
and growth time. These results can then be used in the clonogenic assay to get more precise
CBE factors. A boron compound that has already demonstrated promising in vitro results
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can be evaluated in a small animal model to demonstrate sufficient tumor uptake, followed
by therapy experiments to test its radiobiological effectiveness for BNCT. The tumor model
has to be chosen after considering the targeting properties of the compound and the possible
clinical application for BNCT. In vivo evaluation is best performed by using one large
compound batch.
1) In vitro compound screening at an early stage of compound development
i. Identification of chemical toxicity: The pharmacological toxicity is determined by
incubating cells with boron compound at increasing concentrations using the
colorimetric assay.
ii. Optimization of protocol for the colorimetric assay: The protocol of the colorimetric
assay must be optimized for each cell line. Important parameters are the number of
cells initially plated in each well and the growth time.
iii. Determination of efficacy: The presence of an effect from boron is determined with
the colorimetric assay by comparing cell irradiations of a test compound with those of
boric acid and BPA at the same boron concentration of 5-10 ptg loB/ml.
iv. Optimization of experimental conditions for the clonogenic assay: When a test
compound appears superior to boric acid with the colorimetric assay, experimental
conditions for the clonogenic assay are optimized. Important parameters are the
number of cells plated in the Petri dish at each absorbed dose point and the total
quantity of boron required.
v. Verification of a test compound: Using the clonogenic assay, the efficacy of a test
compound is verified as a promising boron compound for further in vivo study.
2) In vivo evaluation after in vitro testing or where in vitro models are not adequate
i. Biodistribution study: A biodistribution experiment is performed to measure boron
uptake in the tumor and other tissues, such as blood, liver, skin, and other vital organs,
as a function of time after injection. Then, the time for BNCT is determined when the
boron concentration in tumor is highest relative to normal tissue.
ii. Microdistribution study: The microscopic distribution of boron in the tumor is
analyzed using HRQAR with the tissues harvested from the biodistribution study.
iii. Tumor therapy response study: A boron compound that delivers sufficient l°B to
tumor warrants a tumor therapeutic response study to evaluate the effectiveness BNCT
at the time determined in the biodistribution study. The efficacy of a testing compound
may be compared to that of BPA, which is preferentially taken up in many tumors.
iv. Normal tissue response study: The response of normal tissues is characterized under
the same conditions used for the tumor therapy. Normal tissues include CNS, skin, and
the oral mucosa, as well as other critical organs that may have exhibited uptake in the
biodistribution study.
5-3. Considerations for future work
As an attempt to construct a more systematic in vitro compound evaluation for new
compounds which do not need a specific cell line to be tested, the protocol for the
colorimetric assay can be optimized in advance for several tumor cell lines which can be
considered as possible candidates for BNCT. Thus, when promising compounds,
determined by in vitro testing, are evaluated further in a small animal model, the tumor
model for in vivo evaluation can be rationally selected based on tumor cell line results from
in vitro screening.
Tumor therapy response from a pilot study with a double injection of liposomes was
comparable to that from BPA. However, with a double injection of liposomes, two mice
(25 % of total irradiated mice) died for unknown reasons after irradiation. These appear to
be a risk with high blood and liver boron concentrations. The microscopic analysis using
HRQAR indicates that a double injection of liposomes increased the total amount of boron
throughout the tumor rather than improved uniformity of boron uptake, which caused
improved therapy response. Further quantitative analysis with HRQAR at a microscopic
level could be carried out in order to distinguish which part of the EMT-6 tumor would
accumulate more boron from a multiple injection of liposomes. Since the mechanism for
the improved therapy response was not well understood, further investigation to elucidate
the mechanism would be useful, which can be performed simultaneously with therapy
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